0001493152-21-008229.txt : 20210407 0001493152-21-008229.hdr.sgml : 20210407 20210407172442 ACCESSION NUMBER: 0001493152-21-008229 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 52 CONFORMED PERIOD OF REPORT: 20201231 FILED AS OF DATE: 20210407 DATE AS OF CHANGE: 20210407 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Wellness Center USA, Inc. CENTRAL INDEX KEY: 0001516887 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 272980395 STATE OF INCORPORATION: NV FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 333-173216 FILM NUMBER: 21813076 BUSINESS ADDRESS: STREET 1: 2500 WEST HIGGINS ROAD, STE. 780 CITY: HOFFMAN ESTATES STATE: IL ZIP: 60169 BUSINESS PHONE: (847) 925-1885 MAIL ADDRESS: STREET 1: 2500 WEST HIGGINS ROAD, STE. 780 CITY: HOFFMAN ESTATES STATE: IL ZIP: 60169 10-Q 1 form10-q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2020

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ___________ to ___________

WELLNESS CENTER USA, INC.

(Name of small business issuer in its charter)

NEVADA

333-173216

27-2980395

(State or other jurisdiction of

incorporation or organization)

Commission

File Number

(IRS Employee

Identification No.)

145 E. University Boulevard, Tucson, AZ 85705

(Address of Principal Executive Offices)

(847) 925-1885

(Issuer Telephone number)

(Former name or former address, if changed since last report)

Securities registered under Section 12(b) of the Exchange Act:

Title of each class registered:		Name of each exchange on which registered:
None		None

Securities registered under Section 12(g) of the Exchange Act:

Common Stock, par value $0.001

(Title of class)

Indicate by check mark whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes [X] No [ ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or smaller reporting company filer. See definition of “accelerated filer” and “large accelerated filer” in Rule 12b-2 of the Exchange Act (Check one):

Large Accelerated Filer [ ]	Non-Accelerated Filer [ ]
Accelerated Filer [ ]	Smaller Reporting Company [X]
	Emerging growth Company [ ]

Indicate by check mark whether the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.

Yes [ ] No [X]

The number of shares issued and outstanding of each of the issuer’s classes of common equity as of December 31, 2020 was 119,639,577.

FORM 10-Q

WELLNESS CENTER USA, INC.

DECEMBER 31, 2020

TABLE OF CONTENTS

PART I— FINANCIAL INFORMATION

Item 1.	Condensed Consolidated Financial Statements	3
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	18
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	24
Item 4.	Control and Procedures	25

PART II— OTHER INFORMATION


Item 1.	Legal Proceedings	27
Item 1A.	Risk Factors	27
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	28
Item 3.	Defaults Upon Senior Securities	28
Item 4.	Mine Safety Disclosures.	28
Item 5.	Other Information	28
Item 6.	Exhibits	28

SIGNATURE		29

Wellness Center USA, Inc.

Condensed Consolidated Balance Sheets

	December 31,			September 30,
	2020			2020
	(Unaudited)
ASSETS
Current Assets
Cash	$	78,523		$	51,320
Accounts receivable		23,989			-
Inventories		134,522			94,560
Prepaid expenses and other current assets		500			500
Total Current Assets		237,534			146,380

Right of use asset		1,613			6,961
Total Other Assets		1,613			6,961

TOTAL ASSETS	$	239,147		$	153,341

LIABILITIES AND SHAREHOLDERS’ DEFICIT
Current Liabilities
Accounts payable and accrued expenses	$	480,744		$	408,297
Payroll taxes payable – past due		87,834			92,334
Lease liability		1,613			6,961
Lease abandonment liability		672,878			672,878
Loans payable from officers and shareholders, including $504,250 past due at December 31, 2020		1,460,250			1,165,250
Total Current Liabilities		2,703,319			2,345,720

Long-term Liabilities
U.S. Small Business Administration PPP loan payable		37,166			37,166
Total Liabilities		2,740,485			2,382,886

Shareholders’ Deficit
Common stock, par value $0.001, 200,000,000 shares authorized; 119,639,577 and 118,252,077 shares issued and outstanding, respectively		119,639			118,252
Additional paid-in capital		25,104,736			25,053,616
Accumulated deficit		(27,764,061	)		(27,583,363	)
Total Wellness Center USA shareholders’ deficit		(2,539,686	)		(2,411,495	)

Non-controlling interest		38,348			181,950
Total Shareholder’s deficit		(2,501,338	)		(2,229,545	)

TOTAL LIABILITIES AND SHAREHOLDERS’ DEFICIT	$	239,147		$	153,341

The accompanying notes are an integral part of these condensed consolidated financial statements.

Wellness Center USA, Inc.

Condensed Consolidated Statements of Operations

	Three Months Ended
	December 31,
	2020			2019
	(Unaudited)

Trade sales	$	90,499		$	-

Cost of goods sold		80,100			-

Gross profit		10,399			-

Operating expenses		308,541			337,273

Loss from operations		(298,142	)		(337,273	)

Other expense
Interest expense		(26,158	)		(9,323	)
Total other expense		(26,158	)		(9,323	)

NET LOSS		(324,300	)		(346,596	)

Net loss attributable to non-controlling interest		143,602			22,129

NET LOSS ATTRIBUTABLE TO WELLNESS CENTER USA, INC.		(180,698	)		(324,467	)

BASIC AND DILUTED LOSS PER SHARE	$	(0.00	)	$	(0.00	)

WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING
BASIC AND DILUTED		118,960,909			107,497,077

The accompanying notes are an integral part of these condensed consolidated financial statements.

Wellness Center USA, Inc.

Condensed Consolidated Statements of Shareholders’ Deficit (Unaudited)

	Common Stock				Additional Paid-in		Accumulated			Total WCUI			Non-controlling
	Shares		Amount		Capital		Deficit			Deficit			Interest			Total

Balance, September 30, 2020		118,252,077	$	118,252	$	25,053,616	$	(27,583,363	)	$	(2,411,495	)	$	181,950		$	(2,229,545	)

Fair value of vested stock options		-		-		10,882		-			10,882			-			10,882

Fair value of common stock issued for services		1,387,500		1,387		40,238		-			41,625			-			41,625

Net loss for the three months ended December 31, 2020		-		-		-		(180,698	)		(180,698	)		(143,602	)		(324,300	)

Balance, December 31, 2020		119,639,577	$	119,639	$	25,104,736	$	(27,764,061	)	$	(2,539,686	)	$	38,348		$	(2,501,338	)

Balance, September 30, 2019		107,497,077	$	107,497	$	23,777,647	$	(25,362,287	)	$	(1,477,143	)	$	393,149		$	(2,229,545	)

Fair value of vested stock options		-		-		65,738		-			65,738			-			65,738

Contribution of capital by joint venture partner		-		-		25,500		-			25,500			24,500			50,000

Net loss for the three months ended December 31, 2019		-		-		-		(324,467	)		(324,467	)		(22,129	)		(346,596	)

Balance, December 31, 2019		107,497,077	$	107,497	$	23,868,885	$	(25,686,754	)	$	(1,710,372	)	$	395,520		$	(1,314,852	)

The accompanying notes are an integral part of these condensed consolidated financial statements.

Wellness Center USA, Inc.

Condensed Consolidated Statements of Cash Flows

	Three Months Ended
	December 31,
	2020			2019
	(Unaudited)
Cash Flows from Operating Activities
Net loss	$	(324,300	)	$	(346,596	)

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense		-			1,562
Amortization of right-of-use asset		5,348			5,144
Provision for excess and slow moving inventories		50,000			-
Fair value of common shares issued for services		41,625			-
Fair value of stock options issued for services		10,882			65,738
Changes in Assets and Liabilities
(Increase) Decrease in:
Accounts receivable		(23,989	)		-
Inventories		(89,962	)		-
Prepaid expenses and other assets		-			(500	)
(Decrease) Increase in:
Accounts payable and accrued expenses		72,447			84,012
Payroll taxes payable		(4,500	)		-
Lease liability		(5,348	)		(5,144	)
Net cash used in operating activities		(267,797	)		(195,784	)

Cash Flows from Financing Activities
Proceeds from loans payable from officers and shareholders		295,000			135,000
Contribution of capital by joint venture partner		-			50,000
Net cash provided by financing activities		295,000			185,000

Net increase (decrease) in cash		27,203			(10,784	)

Cash beginning of period		51,320			53,147
Cash end of period	$	78,523		$	42,363

Supplemental cash flows disclosures:
Interest paid	$	-		$	-
Taxes paid	$	-		$	-

Supplemental non-cash disclosures:
Initial recognition of right-of-use assets and operating lease liabilities upon adoption of ASC Topic 842	$	-		$	27,841

The accompanying notes are an integral part of these condensed consolidated financial statements.

WELLNESS CENTER USA, INC. AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

FOR THE THREE MONTHS ENDED DECEMBER 31, 2020 AND 2019

NOTE 1 – BASIS OF PRESENTATION

Organization and Operations

Wellness Center USA, Inc. (“WCUI” or the “Company”) was incorporated in June 2010 under the laws of the State of Nevada. The Company initially engaged in online sports and nutrition supplements marketing and distribution. The Company subsequently expanded into additional businesses within the healthcare and medical sectors through acquisitions, including Psoria-Shield Inc. (“PSI”) and StealthCo Inc. (“SCI”), d/b/a Stealth Mark, Inc.

The Company currently operates in the following business segments: (i) distribution of targeted Ultra Violet (“UV”) phototherapy devices for dermatology and sanitation purposes; and (ii) authentication and encryption products and services. The segments are operated, respectively, through PSI and SCI.

Basis of Presentation of Unaudited Financial Information

The accompanying unaudited condensed consolidated financial statements of Wellness Center USA, Inc. and Subsidiaries (the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all normal recurring adjustments considered necessary for a fair presentation have been included. Operating results for the three months ended December 31, 2020 are not necessarily indicative of the results that may be expected for the year ending September 30, 2021.

COVID-19 Considerations

In the period ended December 31, 2020, the COVID-19 pandemic did not have a material net impact on our operating results. In the future, the pandemic may cause reduced demand for our products if, for example, the pandemic results in a recessionary economic environment which negatively effects the consumers who purchase our products.

Our ability to operate without significant negative operational impact from the COVID-19 pandemic will in part depend on our ability to protect our employees and our supply chain. The Company has endeavored to follow the recommended actions of government and health authorities to protect our employees. Since the onset of the COVID-19 pandemic, we maintained the consistency of our operations. However, the uncertainty resulting from the pandemic could result in an unforeseen disruption to our workforce and supply chain (for example an inability of a key supplier or transportation supplier to source and transport materials) that could negatively impact our operations.

Through December 31, 2020, the COVID-19 pandemic has not negatively impacted the Company’s liquidity position as of such date. Through December 31, 2020, the Company continues to generate cash flows through financing activities to meet its short-term liquidity needs, and it expects to maintain access to those shareholder loans. The Company has not observed any material impairments of its assets or a significant change in the fair value of its assets due to the COVID-19 pandemic.

Going Concern

The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying condensed consolidated financial statements, the Company has not yet generated significant revenues and has incurred recurring net losses. During the three months ended December 31, 2020, the Company incurred a net loss of $324,300 and used cash in operations of $267,797, and had a shareholders’ deficit of $2,501,338 as of December 31, 2020. In addition, loans payable of $504,250 and payroll taxes of $87,834 are past due. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to raise additional funds and implement its strategies. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

In addition, the Company’s independent registered public accounting firm, in its report on the Company’s September 30, 2020 financial statements, has raised substantial doubt about the Company’s ability to continue as a going concern.

At December 31, 2020, the Company had cash on hand in the amount of $78,523. The ability to continue as a going concern is dependent on the Company attaining and maintaining profitable operations in the future and raising additional capital soon to meet its obligations and repay its liabilities arising from normal business operations when they come due. Since inception, we have funded our operations primarily through equity and debt financings and we expect to continue to rely on these sources of capital in the future. During the three months ended December 31, 2020, the Company received $295,000 through short-term loans from officers and shareholders.

No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to the Company. Even if the Company is able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing or cause substantial dilution for our stock holders, in case of equity financing.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Consolidation

The consolidated financial statements include the Company’s wholly owned subsidiaries and the accounts of its subsidiaries for which it was determined that Company has operational and management control. The Company’s consolidated subsidiaries and/or controlled entities are as follows:

Name of consolidated subsidiary or entity	State or other jurisdiction of incorporation or organization	Date of incorporation or formation (date of acquisition/disposition, if applicable)	Attributable interest at September 30, 2019			Attributable interest at September 30, 2020
Psoria-Shield Inc. (“PSI”)	The State of Florida	June 2009 (August 2012)		100	%		51	%(1)
StealthCo, Inc. (“StealthCo”)	The State of Illinois	March 2014		100	%		100	%
Psoria Development Company LLC. (“PDC”)	The State of Illinois	January 2015/ November 2018		0	%		0	%
NEO Phototherapy LLC (“NEO”)	The State of Illinois	December 2018		51	%(1)		0	%
Protec Scientific, Inc (“Protec”)	The State of New York	April 2020		0	%		38	%

(1) - Effective April 30, 2020, the Company’s 51% interest in NEO was converted into a 51% interest in PSI.

Use of Estimates

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date, and reported amounts of revenue and expenses during the reporting period. Significant estimates are used in the valuation of accounts receivable and allowance for uncollectible amounts, inventory and obsolescence reserves, accruals for potential liabilities, valuations of stock-based compensation, and realization of deferred tax assets, among others. Actual results could differ from these estimates.

Income (Loss) Per Share

Basic loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of outstanding common shares during the period. Diluted loss per share is computed by dividing the net loss applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. For the three months ended December 31, 2020 and 2019, the basic and diluted shares outstanding were the same, as potentially dilutive shares were considered anti-dilutive. At December 31, 2020 and 2019, the dilutive impact of outstanding stock options of 12,665,238 and 15,037,738 shares, respectively, and outstanding warrants for 67,634,049 and 66,484,049 shares, respectively, have been excluded because their impact on the loss per share is anti-dilutive.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Revenue Recognition

The company records revenue under the guidance of Accounting Standards Codification (“ASC“) 606, Revenue from Contracts with Customers (Topic 606) which requires a company to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services.

For trade sales, the Company generates its revenue from sales contracts with customers with revenues being generated upon the shipment of merchandise, or for consulting services, revenue is recognized in the period services are rendered and earned under service arrangements with clients.

We sell our products through two main sales channels: 1) directly to customers who use our products (the “Direct Channel”) and 2) to distribution partners who resell our products (the “Indirect Channel”).

Under the Direct Channel, we sell our products to and we receive payment directly from customers who purchase our products. Under our Indirect Channel, we have entered into distribution agreements that allow the distributors to sell our products and fulfill performance obligations under the agreements.

We determine revenue recognition through the following steps:

	●	Identification of the contract, or contracts, with a customer

	●	Identification of the performance obligations in the contract

	●	Determination of the transaction price

	●	Allocation of the transaction price to the performance obligations in the contract

	●	Recognition of revenue when, or as, we satisfy a performance obligation.

Revenue is generally recognized upon shipment or when a service has been completed, unless we have significant performance obligations for services still to be completed. We recognize revenue when a material reversal is no longer probable. Payments received before the relevant criteria for revenue recognition are satisfied are recorded as deferred revenue. There was no deferred revenue at December 31, 2020 and 2019.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Non-controlling Interests

In December 2018, PSI entered into a Joint Venture Agreement with GEN2 for further development, marketing, licensing and/or sale of PSI technology and products. Pursuant to the Joint Venture Agreement, the venture will be conducted through NEO Phototherapy, Inc. (“NEO”). PSI and GEN2 will be the members of NEO, owning 50.5% and 36.0%, respectively, of the Units issued in connection with the organization of NEO. An additional 13.5% of such Units will be reserved for issuance as incentives for key employees and consultants. As of September 30, 2019, GEN2 had received $975,000 of investments to contribute to NEO. As of April 30, 2020, the Company controlled 51% of the joint venture, GEN2 controlled 39% and another individual controlled the remaining 10%.

Effective April 30, 2020, the joint venture with GEN2 was reorganized. GEN2 shareholders exchanged their common shares in GEN2, and the individual exchanged his membership interests in NEO, for common shares representing 49% ownership in PSI. The Company retained its common shares in PSI, which provides the Company a 51% economic interest in the PSI technology and products developed by the joint venture. During three months ended December 31, 2020, PSI recorded a loss of $151,433 relating to its operations, of which $74,202 was allocated to the non-controlling interest.

Repayment of the $975,000 investment will begin through and upon the date which PSI has realized and retained cumulative net income/distributable cash in the amount of $300,000. The minority interest of PSI ownership consists of accredited investors, and investment participation of $750,000 from several WCUI officers and directors, including Calvin R. O’Harrow and Roy M. Harsch.

In May 2020, the Company’s subsidiary, PSI, agreed to become a majority shareholder in Protec Scientific, Inc. (“Protec”), a company formed in April 2020 by John Yorke for the purpose of designing, developing and marketing products that use spectral photonic emissions across a variety of applications. As of September 30, 2020, PSI had advanced $191,000 to Protec in furtherance of its agreement to acquire approximately 62% of Protec, with the Company’s share being approximately 32%, based on its PSI ownership. The remaining 30% share is to be attributed to PSI’s minority shareholders, based on their PSI ownership. During the year ended September 30, 2020, Protec received an additional $120,000 from non-affiliated investors, of which $74,400 was recorded to additional paid-in capital and $45,600 to the non-controlling interests. The additional investments gave the non-controlling interests a 38% ownership interest in Protec. During the three months ended December 31, 2020, Protec recorded a loss of $101,492, of which $69,400 was allocated to the non-controlling interests.

Inventories

Inventories are stated at the lower of cost or net realizable value. Cost is computed on a first-in, first-out basis. At December 31, 2020, primarily all of the inventories consisted of raw materials or work-in-progress. The Company provides inventory reserves based on excess and obsolete inventories determined primarily by future demand forecasts. The write down amount, if any, is measured as the difference between the cost of the inventory and net realizable value based upon assumptions about future demand and charged to the provision for inventory, which is a component of cost of sales. At the point of the loss recognition, a new, lower cost basis for that inventory is established, and subsequent changes in facts and circumstances do not result in the restoration or increase in that newly established cost basis. At December 31, 2020, the Company recorded a reserve of $50,000 for excess and slow moving inventories. At September 30, 2020, no reserve was recorded for excess, slow moving or obsolete inventory.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Stock-Based Compensation

The Company periodically issues stock-based compensation to officers, directors, and consultants for services rendered, and as part of financing transactions. Such issuances vest and expire according to terms established at the issuance date. Stock-based payments to officers, directors, employees, and for acquiring goods and services from non-employees, which include grants of employee stock options, are recognized in the financial statements based on their fair values in accordance with Topic 718. Stock option grants, which are generally time vested, will be measured at the grant date fair value and charged to operations on a straight-line basis over the vesting period.

The fair value of the Company’s common stock option and warrant grants are estimated using a Black-Scholes Merton option pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the common stock options, estimated forfeitures and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes option pricing model, and based on actual experience. The assumptions used in the Black-Scholes Merton option pricing model could materially affect compensation expense recorded in future periods.

Recently Issued Accounting Pronouncements

In June 2016, the FASB issued ASU No. 2016-13, Credit Losses - Measurement of Credit Losses on Financial Instruments (“ASC 326”). The standard significantly changes how entities will measure credit losses for most financial assets, including accounts and notes receivables. The standard will replace today’s “incurred loss” approach with an “expected loss” model, under which companies will recognize allowances based on expected rather than incurred losses. Entities will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The standard is effective for interim and annual reporting periods beginning after December 15, 2019. The adoption of ASU 2016-13 is not expected to have a material impact on the Company’s financial position, results of operations, and cash flows.

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

NOTE 3 – LOANS PAYABLE FROM OFFICERS AND SHAREHOLDERS

As of September 30, 2020, loans payable from officers and shareholders of $1,165,250 were outstanding. During the three months ended December 31, 2020, the Company borrowed $295,000 from its officers and shareholders. All of the loans are unsecured, have an interest rate of eight percent and are due one year from the date of issuance. As of December 31, 2020, loans payable to officers and shareholders of $1,460,250 were outstanding and $504,250 was past due.

NOTE 4 – U.S. SMALL BUSINESS ADMINISTRATION LOAN PAYABLE

During the year ended September 30, 2020, the Company’s subsidiary, PSI, entered into a loan agreement with the United States Small Business Administration (SBA) under which the Company borrowed $37,166. The loan is unsecured, accrues interest at 1.0% and is due on April 23, 2022. Beginning in March 2021, PSI is required to make monthly interest payments and all principal and unpaid interest is due in April 2022. If PSI meets certain criteria as defined in the agreement, the loan may be forgiven at which time the Company would recognize a gain on debt forgiveness. As of the date of this filing, the Company had not yet applied for forgiveness of the loan. As of December 31, 2020, a total of $37,166 was outstanding on the loan.

NOTE 5 – LEASE LIABILITIES

Operating Lease

In February 2019, the Company’s PSI subsidiary entered into a 24-month non-cancellable lease for its office facilities that will require monthly payments of $1,850 through January 2021. The Company adopted ASU 2016-02, Leases, effective October 1, 2019, which requires a lessee to record a right-of-use asset and a corresponding lease liability at the inception of the lease initially measured at the present value of the lease payments. The Company classified the lease as an operating lease and determined that the value of the lease asset and liability at the inception of the lease was $27,841, using a discount rate of 4.00%. As of September 30, 2020, the value of the lease asset and liability was $6,961, respectively. During the three months ended December 31, 2020, the Company made payments of $5,348 towards the lease liability. As of December 31, 2020, the lease liability amounted to $1,613.

ASU 2016-02 requires recognition in the statement of operations of a single lease cost, calculated so that the cost of the lease is allocated over the lease term, generally on a straight-line basis. Rent expense for the three months ended December 31, 2020 was $5,348. During the three months ended December 31, 2020, the Company reflected amortization of the right of use asset of $5,348 related to this lease, resulting in a net asset balance of 1,613 as of December 31, 2020.

Other Leases

The Company leased its corporate office facility in Hoffman Estates, Illinois pursuant to a non-cancellable lease initiated in July 2016 and expiring February 28, 2024. The lease terms require a monthly payment of approximately $11,000. The Company vacated the facility in April 2019, in favor of its present facilities in Tucson AZ, which are provided by a shareholder on a rent-free basis. The Company is in negotiations with the owners regarding the settlement of its lease obligations and expects that the property will be subleased or a settlement with the landlord will be reached at an amount significantly less than the remaining payment obligations. At the date of abandonment, the Company had a remaining lease obligation of $631,587.

On or about June 29, 2020, we received notice that Hanover Hoffman Estates, LLC (“HHE”), filed case number 2020L006092 in the Circuit Court of Cook County alleging our failure to pay Base Rent and abandonment of certain office space in Hoffman Estates, Illinois subject to a Commercial Lease dated May 26, 2016. HHE seeks at least $672,878 in base rent and other amounts under the lease, as well as treble damages from our ex-CEO and two past Directors who were serving on our Board as of the date of the lease. We are currently evaluating the allegations, defenses and alternate actions. As of December 31, 2020, the Company has recorded the full amount of the judgement due.

NOTE 6 – SHAREHOLDERS’ EQUITY

Restricted Stock Grants

In April 2020, the Company’s Board of Directors approved the issuance of a combined total of 20,170,000 restricted shares of the Company’s common stock to its Officers and Directors. A total of 7,120,000 shares vested in April 2020, while 1,800,000 will vest monthly from April 2020 through March 2021, and 11,250,000 will vest monthly from April 2020 through March 2023. Of the 13,050,000 shares that vest over time, a total of 1,387,500 shares vested during the three months ended December 31, 2020.

The following table summarizes restricted common stock activity:

	Number of Restricted Shares			Fair Value			Weighted Average Grant Date Fair Value

Non-vested, September 30, 2020		10,275,000		$	308,250		$	0.03
Granted		-			-			-
Vested		(1,387,500	)		(41,625	)		0.03
Forfeited		-			-			-
Non-vested, December 31, 2020		8,887,500		$	266,625		$	0.03

During the three months ended December 31, 2020, the Company recorded $41,625 of stock compensation for the value of restricted common stock vesting during the period, and as of December 31, 2020, unvested compensation of $266,625 remained that will be amortized over the remaining vesting period.

Stock Options

On December 22, 2010, effective retroactively as of June 30, 2010, the Company’s Board of Directors approved the adoption of the “2010 Non-Qualified Stock Option Plan” (“2010 Option Plan”) by unanimous consent. The 2010 Option Plan was initiated to encourage and enable officers, directors, consultants, advisors and key employees of the Company to acquire and retain a proprietary interest in the Company by ownership of its common stock. A total of 7,500,000 of the authorized shares of the Company’s common stock may be subject to, or issued pursuant to, the terms of the plan. Effective January 1, 2018, the Board of Directors approved to increase the number of authorized shares of the Company’s common stock that may be subject to, or issued pursuant to, the terms of the plan from 7,500,000 to 30,000,000.

NOTE 6 – SHAREHOLDERS’ EQUITY (CONTINUED)

Stock Options (continued)

The Company’s policy is to recognize compensation cost for awards with only service conditions and a graded vesting schedule on a straight-line basis over the requisite service period for the entire award. Additionally, the Company’s policy is to issue new shares of common stock to satisfy stock option exercises. The Company applied fair value accounting for all share based payments awards. The fair value of each option granted is estimated on the date of grant using the Black-Scholes option-pricing model.

The table below summarizes the Company’s stock option activities for the three months ended December 31, 2020:

	Number of Option Shares			Exercise Price Range Per Share		Weighted Average Exercise Price

Balance, September 30, 2020		14,127,738		$	0.03 - 2.00	$	0.29
Granted		-			-		-
Cancelled		-			-		-
Exercised		-			-		-
Expired		(1,462,500	)		0.14 - 2.00		1.41
Balance, December 31, 2020		12,665,238		$	0.03 - 0.40	$	0.10
Vested and exercisable, December 31, 2020		9,702,738		$	0.03 - 0.40	$	0.12

Unvested, December 31, 2020		2,962,500		$	0.04	$	0.04

The following table summarizes information concerning outstanding and exercisable options as of December 31, 2020:

		Options Outstanding						Options Exercisable
Range of Exercise Prices		Number Outstanding		Average Remaining Contractual Life (in years)		Weighted Average Exercise Price		Number Exercisable		Average Remaining Contractual Life (in years)		Weighted Average Exercise Price

$	0.03 - 0.39		12,602,738		6.75	$	0.09		9,640,238		5.85	$	0.12
	0.40		62,500		1.25		0.40		62,500		1.25		0.40
$	0.03 - 0.40		12,665,238		6.72	$	0.10		9,702,738		5.82	$	0.12

During the three months ended December 31, 2020, the Company recorded $10,882 of stock compensation for the value of options vesting during the period, and as of December 31, 2020, unvested compensation of $85,882 remained that will be amortized over the remaining vesting period.

The total aggregate intrinsic value for option shares outstanding at December 31, 2020 was $126,625. As of December 31, 2020, there were 17,334,762 shares of stock options remaining available for issuance under the 2010 Plan.

NOTE 6 – SHAREHOLDERS’ EQUITY (CONTINUED)

Stock Warrants

The table below summarizes the Company’s warrants activities for the three months ended December 31, 2020:

	Number of Warrant Shares		Exercise Price Range Per Share		Weighted Average Exercise Price

Balance, September 30, 2020		67,634,049	$	0.07 - 0.40	$	0.16
Granted		-		-		-
Cancelled		-		-		-
Exercised		-		-		-
Expired		-		-		-
Balance, December 31, 2020		67,634,049	$	0.07 - 0.40	$	0.16
Vested and exercisable, December 31, 2020		67,634,049	$	0.07 - 0.40	$	0.16

The following table summarizes information concerning outstanding and exercisable warrants as of December 31, 2020:

		Warrants Outstanding						Warrants Exercisable
Range of Exercise Prices		Number Outstanding		Average Remaining Contractual Life (in years)		Weighted Average Exercise Price		Number Exercisable		Average Remaining Contractual Life (in years)		Weighted Average Exercise Price

$	0.12 – 0.20		60,429,384		1.74	$	0.15		60,429,384		1.74	$	0.15
	0.21 – 0.40		7,204,665		0.64		0.26		7,204,665		0.64		0.26

$	0.12 – 0.67		67,634,049		1.62	$	0.16		67,634,049		1.62	$	0.16

There was no aggregate intrinsic value for warrant shares outstanding at December 31, 2020.

NOTE 7 – SEGMENT REPORTING

Reportable segments are components of an enterprise about which separate financial information is available and that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company’s reportable segments are based on products and services, geography, legal structure, management structure, or any other manner in which management disaggregates a company.

The Company operates in the following business segments:

(i) Medical Devices: which stems from PSI, its wholly-owned subsidiary acquired on August 24, 2012, a developer, manufacturer, marketer and distributer of targeted Ultra Violet (“UV”) phototherapy devices for the treatment of skin diseases, and for sanitation purposes.

(ii) Authentication and Encryption Products and Services: which stems from StealthCo, its wholly-owned subsidiary formed on March 18, 2014, which has engaged in the business of selling, licensing or otherwise providing certain authentication and encryption products and services since acquisition of certain assets from SMI on April 4, 2014.

The detailed segment information of the Company is as follows:

Assets By Segment

	December 31, 2020
	Corporate		Medical Devices		Authentication and Encryption		Total
ASSETS
Current Assets
Cash	$	8,178	$	67,709	$	2,636	$	78,523
Accounts receivable		-		23,989		-		23,989
Inventories		-		134,522		-		134,522
Prepaid expenses and other current assets		500		-		-		500
Total current assets		8,678		226,220		2,636		237,534

Right of use asset		-		1,613		-		1,613
Total other assets		-		1,613		-		1,613

TOTAL ASSETS	$	8,678	$	227,833	$	2,636	$	239,147

Operations by Segment

	For the Three Months Ended
	December 31, 2020
	Corporate			Medical Devices			Authentication and Encryption			Total

Trade sales	$	-		$	90,499		$	-		$	90,499

Cost of goods sold		-			80,100			-			80,100

Gross profit		-			10,399			-			10,399

Operating expenses		49,109			256,471			2,961			308,541

Loss from operations	$	(49,109	)	$	(246,072	)	$	(2,961	)	$	(298,142	)

	For the Three Months Ended
	December 31, 2019
	Corporate			Medical Devices			Authentication and Encryption			Total

Trade sales	$	-		$	-		$	-		$	-

Cost of goods sold		-			-			-			-

Gross profit		-			-			-			-

Operating expenses		98,462			175,286			63,525			337,273

Loss from operations	$	(98,462	)	$	(175,286	)	$	(63,525	)	$	(337,273	)

NOTE 8 – LEGAL MATTERS

The Company is periodically engaged in legal proceedings arising from and relating to its business operations. Except as otherwise described herein, we currently are not involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our Company or any of our subsidiaries, threatened against or affecting our Company, our common stock, any of our subsidiaries or of our Company’s or our subsidiaries’ officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect on our financial condition or results of operations.

We continue efforts to preserve revenue and reduce operating expenses through actions including, but not limited to, facilities consolidation and staff reductions, which we hope to implement through negotiated transactions with lessors, employees and other third parties. Such actions may result in disputes with and claims by such parties which, if not resolved through negotiations, may impact negatively the Company’s ability to continue as a going concern. To date, the Company has negotiated settlement of all ex-employee wage and benefits claims except for two. The first regards unpaid wages claimed due together with interest at the rate of 4% per annum on such amount as the Company originally agreed upon in settlement negotiations. The ex-employee claims additional amounts due for certain statutory damages under the Illinois Wage Payment and Collection which currently could exceed $21,600.00 and would increase at the rate of 2% of the wages due per month plus attorneys’ fees if the employee elects to file suit for a violation of the Act and is successful in obtaining a judgment on his claim.

The second claim was filed with the Illinois Department of Labor asserting a violation of the Illinois Wage Payment and Collection Act by the Company’s former CEO. That claim alleges unpaid wages in the amount of $158,714.60 and unpaid vacation pay in the amount of $20,833.33 for a total amount of $179,547.90, as well as certain statutory damages including, but not limited to, 2% of the wages due per month plus attorneys’ fees if the ex-CEO elects to file suit for a violation of the Act and is successful in obtaining a judgment on his claim. The Company has filed its response to such claim with the Department denying the substantive allegations therein and asserting certain factual and legal defenses, including breach of fiduciary duty, as a bar to all claimed compensation. The claim remains pending, but as the date hereof, no suit has been filed against the Company asserting a violation of the Act based on said claim.

NOTE 9 – SUBSEQUENT EVENTS

Subsequent to December 31, 2020, the Company borrowed $355,000 from its officers and shareholders. All of the loans are unsecured, have an interest rate of eight percent and are due one year from the date of issuance.

On April 1, 2021, the Company’s Board of Directors approved the issuance of a combined total of 3,750,000 restricted shares of the Company’s common stock to certain of its Officers and Directors for future services to be performed. The shares vest monthly from April 2023 through March 2024. The fair value of the shares on the date of grant was $187,500.

The Board also approved the issuance of a combined total of 10,085,714 restricted shares of the Company’s common stock to certain of its Officers and Directors in connection with their officer and shareholder loans. A total of 7,060,000 of the shares vested upon grant and 3,025,714 shares vest in April 2025. The fair value of the shares on the date of grant was $504,286.

On April 1, 2021, the Company’s Board of Directors approved the grant of stock options to its Chief Executive Officer (CEO) to purchase 1,300,000 shares of the Company’s common stock with an exercise price of $0.05 per share. The options expire ten years from the date of grant. The option grants are for future services to be performed by the CEO. The shares vest monthly from April 2023 through March 2024. The fair value of the shares on the date of grant was approximately $65,000.

The Board also approved the grant of stock options to its CEO to purchase 13,449,429 shares of the Company’s common stock with an exercise price of $0.05 per share. The options expire ten years from the date of grant. The option grants are in connection with his officer and shareholder loans. A total of 9,052,500 of the shares vested upon grant and 4,396,929 shares vest in April 2025. The fair value of the shares on the date of grant was approximately $670,000. In connection with the option grants, the CEO agreed to cancel 5,277,778 of his warrant shares that were scheduled to expire from September 2021 through December 2021.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Forward Looking Statements

Except for historical information, the following discussion contains forward-looking statements based upon current expectations that involve certain risks and uncertainties. Such forward-looking statements include statements regarding, among other things, (a) our projected sales and profitability, (b) our growth strategies, (c) anticipated trends in our industry, (d) our future financing plans, (e) our anticipated needs for working capital, (f) our lack of operational experience and (g) the benefits related to ownership of our common stock. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “will,” “should,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. This information may involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from the future results, performance, or achievements expressed or implied by any forward-looking statements. These statements may be found under “Description of Business,” and “Analysis of Financial Condition and Results of Operations”, as well as in this Report generally. Actual events or results may differ materially from those discussed in forward-looking statements as a result of various factors, including, without limitation, the risks outlined under “Risk Factors” in our Annual Report on Form 10-K and in other Reports we have filed with the Securities and Exchange Commission, as well as matters described in this Report generally. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements contained in this Report will in fact occur as projected.

The following discussion and analysis provides information which management believes is relevant to an assessment and understanding of our results of operations and financial condition. The discussion should be read along with our financial statements and notes thereto. This section includes a number of forward-looking statements that reflect our current views with respect to future events and financial performance. You should not place undue certainty on these forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from our predictions.

Description of Business

Background.

Wellness Center USA, Inc. (“WCUI” or the “Company”) was incorporated in June 2010 under the laws of the State of Nevada. We initially engaged in online sports and nutrition supplements marketing and distribution. We subsequently expanded into additional businesses within the healthcare and medical sectors through acquisitions, including Psoria-Shield Inc. (“PSI”) and StealthCo Inc. (“SCI”), d/b/a Stealth Mark, Inc.

The Company currently operates in two business segments: (i) distribution of targeted Ultra Violet (“UV”) phototherapy devices for dermatology and sanitation purposes; and (ii) authentication and encryption products and services. The segments are conducted through our wholly-owned subsidiaries, PSI and SCI.

COVID-19 Uncertainties

In March 2020, the World Health Organization declared the outbreak of COVID-19 a global pandemic. The responses by federal, state and local governments to restrict public gatherings and travel rapidly grew to include stay-at-home orders, school closures and mandatory restrictions on non-essential businesses and services that has adversely affected workforces, economies, and financial markets resulting in a significant economic downturn. The Company’s corporate office is located in Tucson, Arizona and its manufacturing facility is in Utica, New York. Since March 2020, we have been following the recommendations of local health authorities to minimize exposure risk for our employees, including temporary closures of our offices and having employees work remotely to the extent possible. The order, which has subsequently been modified to provide for a gradual re-opening of businesses and travel, is to remain in place until further notice.

While this disruption is currently expected to be temporary, there is considerable uncertainty around the duration. We are actively monitoring the COVID-19 situation and its impact in the markets we serve. We are taking all precautionary measures as directed by health authorities and local and national governments. Due to continuing uncertainties regarding the ultimate scope and trajectory of COVID-19’s spread and evolution, it is impossible to predict the total impact that the pandemic will have on our business. If public and private entities continue to implement restrictive measures, the material adverse effect on our business, results of operations, financial condition and cash flows could persist.

PSI

PSI was incorporated under the laws of the state of Florida on June 17, 2009. We acquired all of the issued and outstanding shares of stock in PSI on August 24, 2012.

Joint Ventures

In December 2018, PSI entered into a Joint Venture Agreement with GEN2 for further development, marketing, licensing and/or sale of PSI technology and products. Pursuant to the Joint Venture Agreement, the venture will be conducted through NEO Phototherapy, Inc. (“NEO”). PSI and GEN2 will be the members of NEO, owning 50.5% and 36.0%, respectively, of the Units issued in connection with the organization of NEO. An additional 13.5% of such Units will be reserved for issuance as incentives for key employees and consultants. As of September 30, 2020, GEN2 had received $975,000 of investments to contribute to NEO. As of April 30, 2020, the Company controlled 51% of the joint venture, GEN2 controlled 39% and another individual controlled the remaining 10%.

Psoria-Light

PSI designs, develops and markets a targeted ultraviolet (“UV”) phototherapy device called the Psoria-Light. The Psoria-Light is designated for use in targeted PUVA photochemistry and UVB phototherapy and is designed to treat certain skin conditions including psoriasis, vitiligo, atopic dermatitis (eczema), seborrheic dermatitis, and leukoderma.

Psoriasis, eczema, and vitiligo, are common skin conditions that can be challenging to treat, and often cause the client significant psychosocial stress. Clients may undergo a variety of treatments to address these skin conditions, including routine consumption of systemic and biologic drug therapies which are highly toxic, reduce systemic immune system function, and come with a host of chemotherapy-like side effects. Ultraviolet (UV) phototherapy is a clinically validated alternate treatment modality for these disorders.

Traditionally, “non-targeted” UV phototherapy was administered by lamps that emitted either UVA or UVB light to both diseased and healthy skin. While sunblocks or other UV barriers may be used to protect healthy skin, the UV administered in this manner must be low dosage to avoid excessive exposure of healthy tissue. Today, “targeted” UV phototherapy devices administer much higher dosages of light only to affected tissue, resulting in “clearance” in the case of psoriasis and eczema, and “repigmentation” in the case of vitiligo, at much faster rates than non-targeted (low dosage) UV treatments.

Targeted UV treatments are typically administered to smaller total body surface areas, and are therefore used to treat the most intense parts of a client’s disease. Non-targeted UV treatment is typically used as a follow-up and for maintenance, capable of treating large surfaces of the body. Excimer laser devices (UVB at 308nm) are expensive and consume dangerous chemicals (Xenon and Chlorine). Mercury lamp devices (UVB and/or UVA) require expensive lamp replacements regularly and require special disposal (due to mercury content). Additionally, mercury lamp devices typically deliver wavelengths of light below 300nm. While within the UVB spectrum, it has been shown that wavelengths below 300nm produce significantly more “sunburn” type side effects than do wavelengths between 300 and 320nm without improvement in therapeutic benefit.

The Psoria-Light is a targeted UV phototherapy device that produces UVB light between 300 and 320 nm as well as UVA light between 350 and 395nm. It does not require consumption of dangerous chemicals or require special environmental disposal, and is cost effective for clinicians, which should result in increased patient access to this type of treatment. It has several unique and advanced features that we believe will distinguish it from the non-targeted and targeted UV phototherapy devices that are currently being used by dermatologists and other healthcare providers. These features include the following: the utilization of deep narrow-band UVB (“NB-UVB”) LEDs as light sources; the ability to produce both UVA or NB-UVB therapeutic wavelengths; an integrated high resolution digital camera and client record integration capabilities; the ability to export to an external USB memory device a PDF file of treatment information including a patent pending graph that includes digital images plotted against user tracked metrics which can be submitted to improve medical reimbursements; an accessory port and ability to update software; ease of placement and portability; advanced treatment site detection safety sensor; international language support; a warranty which includes the UV lamp(s); and a non-changeable treatment log (that does not include HIPPA information).

The Psoria-Light consists of three components: a base console, a color display with touchscreen control, and a hand-held delivery device with a conduit (or tether) between the handheld device and the base console. PSI requires clearance by the United States Food and Drug Administration (“FDA”) to market and sell the device in the United States as well as permission from TUV SUD America Inc., PSI’s Notified Body, to affix the CE mark to the Psoria-Light in order to market and sell the device in countries of the European Union.

To obtain FDA clearance and permission to affix the CE mark, PSI was required to conduct EMC and electrical safety testing, which it completed in the second quarter of 2011. PSI received FDA clearance on February 11, 2011 (no. K103540) and was granted permission to affix the CE mark on November 10, 2011. In its 510(k) application with the FDA (application number K103540), PSI asserted that the Psoria-Light was “substantially equivalent” in intended use and technology to two predicate devices, the X -Trac Excimer Laser, which has wide acceptance in the medical billing literature and has a large installed base in the U.S., and the Dualight, another competing targeted UV phototherapy device.

PSI has established an ISO 13485 compliant quality system for the Psoria-Light, which was first audited in the third quarter of 2011. This system is intended to ensure PSI devices will be manufactured in a controlled and reliable environment and that its resources follow similar practices and is required for sales in countries requiring a CE mark. PSI has also received Certified Space Technology designation from the Space Foundation, based on PSI’s incorporation of established NASA-funded LED technology.

PSI began Psoria-Light Beta deployment in January 2012. It is currently operating at a loss, and there is no assurance that its business development plans and strategies will ever be successful. PSI’s success depends upon the acceptance by healthcare providers and clients of Psoria-Light treatment as a preferred method of treatment for psoriasis and other UV-treatable skin conditions. Psoria-Light treatment appears to have been beneficial to clients, without demonstrable harmful side effects or safety issues, as evidenced by more than 10,000 treatments completed on more than 1,000 clients, domestically and Mexico, since 2012. In order for the Company to continue PSI operations, it will need additional capital and it will have to successfully coordinate integration of PSI operations without materially and adversely affecting continuation and development of other Company operations.

SCI

SCI was incorporated under the laws of the state of Illinois on March 18, 2014. SCI acquired certain Stealth Mark assets on April 4, 2014 and operates as a wholly-owned subsidiary of the Company. It is a provider of: a) Stealth Mark encryption and authentication solutions offering advanced technologies within the security and supply chain management vertical sectors (Intelligent Microparticles), and b) advanced data intelligence services offering proprietary, unprecedented, and actionable technology for industries, companies, and agencies on a global scale (ActiveDuty™).

Intelligent Microparticles

SCI provides clients premiere authentication technology for the protection of a variety of products and brands from illicit counterfeiting and diversion activities. Its technology is applicable to a wide range of industries affected by counterfeiting, diversion and theft including, but not limited to, pharmaceuticals, defense/aerospace, automotive, electronics, technology, consumer and personal care goods, designer products, beverage/spirits, and many others.

SCI delivers the client a complete, simple to use, easy to implement, and cost effective turnkey system that is extremely difficult to compromise. SCI’s technology includes a combination of proprietary software and intelligent microparticle marks that are unduplicatable and undetectable to the human eye. These taggants are created with proprietary materials that create unique numerical codes that are assigned meaning by the client and are machine readable without the use of rare earth or chemical tracers. They have been used in covert and overt operations with easy to implement technology and do-it-yourself in-the-field forensic caliber verification.

In April 2018, the Company’s subsidiary, SCI, concluded licensing of a patent for technology that is the next generation of Stealth Mark. Working with researchers at the Oak Ridge National Labs, the patent signifies development of a new technology that will generate an invisible marking system with attributes currently unavailable in the anti-counterfeit marketplace today. The formula and techniques have been shown through extensive testing to be resilient to manufacturing processes and can be used on a wide range of materials from woven and non-woven fabrics, cardboard, metal, concrete, plastics, leather, wood, and paper. In addition, the complexity of the information that can be encoded with the system makes counterfeiting difficult.

ActiveDuty™

SCI’s ActiveDuty™ data intelligence services offer unique, unprecedented, actionable technology for industries, companies, and agencies on a global scale. Comprised of a suite of powerful analytical tools, including artificial intelligence and social-psychology, the service provides timely and actionable intelligence to clients. ActiveDuty™ is adaptable to a broad spectrum of illicit activities within both private and public sectors such as, but not limited to, counterfeiting, sex and human trafficking, money laundering, and a variety of other markets.

The proprietary algorithmic architecture of ActiveDuty™ creates the first systemic reporting mechanism to deliver strategic and tactical results supported by an intense worldwide analysis of patterns of human behavior. The ActiveDuty™ global framework is heuristic in nature, capable of comprehending big data across the digital spectrum and speaks all the major languages. Up until now, there has not existed a unified system that could actively measure this lifecycle that is a collection of discreet and seemingly random behaviors of criminals anywhere within the digital domain. Criminals change their identities but not their basic behaviors.

Analysis of Financial Condition and Results of Operations

Results of Operations for the three months ended December 31, 2020 compared to the three months ended December 31, 2019.

Revenue and Cost of Goods Sold

Revenue for the three months ended December 31, 2020 was $90,499. There was no revenue, cost of sales or gross profit for the three months ended December 31, 2019. The increase in 2020 was due to the increase in revenues at PSI, as there was no revenue at SCI for each period. Cost of sales for the three months ended December 31, 2020 was $80,100. Gross profit for the three months ended December 31, 2020 was $10,399.

Operating Expenses

Operating expenses for the three months ended December 31, 2020 and 2019 were $308,541 and $337,273, respectively. The decrease in operating expenses in 2020 was due primarily to the decrease in labor and facility costs at SCI, offset by an increase in operating expenses at PSI, primarily labor-related costs.

Other Expenses

Other expenses during the three months ended December 31, 2020 and 2019 consisted of $26,158 and $9,323 of interest expense, respectively.

Net Loss

Our net loss for the three months ended December 31, 2020 was $324,300, compared to a net loss of $346,596 for the three months ended December 31, 2019. The decrease in the net loss in 2020 was primarily due to the decrease in operating expenses.

Results of Operations by Segment

The Company currently maintains two business segments:

	(i)	Medical Devices: which it provided through PSI, its wholly-owned subsidiary acquired on August 24, 2012, a developer, manufacturer, marketer and distributer of targeted Ultra Violet (“UV”) phototherapy devices for the treatment of skin diseases; and

	(ii)	Authentication and Encryption Products and Services: which it provided through SCI, its wholly-owned subsidiary that on April 4, 2014 acquired certain assets of SMI Holdings, Inc. d/b/a Stealth Mark, Inc., including Stealth Mark tradenames and marks, and related encryption and authentication solutions offering advanced product security technologies within the security and supply chain management vertical sectors.

The detailed segment information of the Company is as follows:

Operations by Segment

	For the Three Months Ended
	December 31, 2020
	Corporate			Medical Devices			Authentication and Encryption			Total

Trade sales	$	-		$	90,499		$	-		$	90,499

Cost of goods sold		-			80,100			-			80,100

Gross profit		-			10,399			-			10,399

Operating expenses		49,109			256,471			2,961			308,541

Loss from operations	$	(49,109	)	$	(246,072	)	$	(2,961	)	$	(298,142	)

	For the Three Months Ended
	December 31, 2019
	Corporate			Medical Devices			Authentication and Encryption			Total

Trade sales	$	-		$	-		$	-		$	-

Cost of goods sold		-			-			-			-

Gross profit		-			-			-			-

Operating expenses		98,462			175,286			63,525			337,273

Loss from operations	$	(98,462	)	$	(175,286	)	$	(63,525	)	$	(337,273	)

Revenue for the Medical Devices segment for the three months ended December 31, 2020 was $90,499. There was no revenue or cost of goods sold for the Medical Devices segment for the three months ended December 31, 2019. The increase in sales in 2020 was due to the launch of PSI’s new FDA approved medical device named Aurora. Cost of sales during the three months ended December 31, 2020 was $80,100 and gross profit was $10,399. Operating expenses for the three months ended December 31, 2020 and 2019 was $256,471 and $175,286, respectively. The increase in operating expenses in 2020 was primarily due to the increase in labor-related costs and production-related costs. The loss from operations for the three months ended December 31, 2020 and 2019 was $246,072 and $175,286, respectively.

There was no revenue or cost of sales for the Authentication and Encryption segment for the three months ended December 31, 2020 and 2019. Operating expenses for the three months ended December 31, 2020 and 2019 was $2,961 and $63,525, respectively. The decrease in operating expenses in 2020 was primarily due to the decrease in labor and facility costs. The loss from operations for the three months ended December 31, 2020 and 2019 was $2,961 and $63,525, respectively.

The Corporate segment primarily provides executive management services for the Company. Operating expenses for the three months ended December 31, 2020 and 2019 was $49,109 and $98,462, respectively. The decrease in operating expenses in 2020 was due primarily to the decrease in professional fees. The loss from operations for the three months ended December 31, 2020 and 2019 was $49,109 and $98,462, respectively.

Liquidity and Capital Resources

Comparison of three months ended December 31, 2020 and 2019

As of December 31, 2020, we had $78,523 in cash, negative working capital of $2,465,785 and an accumulated deficit of $27,764,061.

As of December 31, 2019, we had $42,363 in cash, negative working capital of $1,337,549 and an accumulated deficit of $25,686,754.

Cash flows used in operating activities

During the three months ended December 31, 2020, the Company used cash flows in operating activities of $267,797, compared to $195,784 used in the three months ended December 31, 2019. During the three months ended December 31, 2020, the Company incurred a net loss of $324,300 and $57,855 of non-cash expenses, compared to a net loss of $346,596 and $72,444 of non-cash expenses during the three months ended December 31, 2019.

Cash flows used in investing activities

During the three months ended December 31, 2020 and 2019, the Company had no cash flows from investing activities.

Cash flows provided by financing activities

During the three months ended December 31, 2020, the Company had proceeds from loans payable from officers and shareholders of $295,000. During the three months ended December 31, 2019, the Company had proceeds from loans payable from officers and shareholders of $135,000 and proceeds of $50,000 from contributions of capital by its joint venture partner.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

Summary of Critical Accounting Policies.

The Company has identified critical accounting policies that, as a result of the judgments, uncertainties, uniqueness and complexities of the underlying accounting standards and operations involved could result in material changes to its financial condition or results of operations under different conditions or using different assumptions. The Company’s most critical accounting policies include, but are not limited to, those related to fair value of financial instruments, revenue recognition, stock based compensation for obtaining employee services, and equity instruments issued to parties other than employees for acquiring goods or services. Details regarding the Company’s use of these policies and the related estimates are described in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2020, filed with the Securities and Exchange Commission on February 8, 2021. There have been no material changes to the Company’s critical accounting policies that impact the Company’s financial condition, results of operations or cash flows for the three months ended December 31, 2020.

Recently Issued Accounting Pronouncements

See Management’s discussion of recent accounting policies included in footnote 2 to the condensed consolidated financial statements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not required for smaller reporting Companies.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Regulations under the Securities Exchange Act of 1934 (the “Exchange Act”) require public companies to maintain “disclosure controls and procedures,” which are defined as controls and other procedures that are designed to ensure that information required to be disclosed by the issuer in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. A material weakness is a control deficiency (within the meaning of the Public Company Accounting Oversight Board (PCAOB) Auditing Standard No. 2) or combination of control deficiencies that result in more than a remote likelihood that a material misstatement of the annual or interim financial statements will not be prevented or detected.

The Company carried out an evaluation, with the participation of the Company’s management, including the Company’s Chief Executive Officer (“CEO”), of the effectiveness of the Company’s disclosure controls and procedures (as defined under Rule 13a-15(e) under the Exchange Act) as of December 31, 2020, the end of the period covered by this report. Based upon that evaluation, the Company’s CEO concluded that the Company’s disclosure controls and procedures are not effective at the reasonable assurance level due to the material weaknesses described below:

1. The lack of an independent audit committee and the lack of internal personnel necessary to provide accurate and timely regulatory filings.

2. The Company does not have written documentation of its internal control policies and procedures. Written documentation of key internal controls over financial reporting is a requirement of Section 404 of the Sarbanes-Oxley Act which is applicable to the Company. Management evaluated the impact of its failure to have written documentation of its internal controls and procedures on its assessment of its disclosure controls and procedures and has concluded that the control deficiency that resulted represented a material weakness.

3. The Company does not have sufficient segregation of duties within its accounting functions, which is a basic internal control. Due to its size and nature, segregation of all conflicting duties may not always be possible and may not be economically feasible. However, to the extent possible, the initiation of transactions, the custody of assets and the recording of transactions should be performed by separate individuals. Management evaluated the impact of its failure to have segregation of duties on its assessment of its disclosure controls and procedures and has concluded that the control deficiency that resulted represented a material weakness.

4. The Company does not have sufficient segregation of duties so that one person can initiate, authorize and execute transactions.

5. The Company has insufficient full time personnel with an appropriate level of technical accounting knowledge to SEC reporting requirements to timely meet the filing requirements.

In light of the material weaknesses, the management of the Company performed additional analysis and other post-closing procedures to ensure our consolidated financial statements were prepared in accordance with the accounting principles generally accepted in the United States of America. Accordingly, we believe that our consolidated financial statements included herein fairly present, in all material respects, our consolidated financial condition, consolidated results of operations and cash flows as of and for the reporting periods then ended.

Management’s Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Exchange Act as a process designed by, or under the supervision of, the issuer’s principal executive and principal financial officer and effected by the issuer’s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America and includes those policies and procedures that:

● Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the issuer;

● Only in accordance with authorizations of management and directors of the issuer; and provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with accounting principles generally accepted in the United States of America and that receipts and expenditures of the Company are being made;

● Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the issuer’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Because of the inherent limitations of internal control, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.

As of the end of our most recent fiscal year, management assessed the effectiveness of our internal control over financial reporting based on the criteria for effective internal control over financial reporting established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) and SEC guidance on conducting such assessments. Based on that evaluation, they concluded that, as of September 30, 2020, such internal control over financial reporting was not effective. This was due to deficiencies that existed in the design or operation of our internal control over financial reporting that adversely affected our internal controls and that may be considered to be material weaknesses.

The matters involving internal control over financial reporting that our management considered to be material weaknesses under the standards of the Public Company Accounting Oversight Board were: (1) lack of a functioning audit committee due to a lack of a majority of independent members and a lack of a majority of outside directors on our board of directors, resulting in ineffective oversight in the establishment and monitoring of required internal controls and procedures; and (2) inadequate segregation of duties consistent with control objectives of having segregation of the initiation of transactions, the recording of transactions and the custody of assets. The aforementioned material weaknesses were identified by our Chief Executive Officer in connection with the review of our financial statements as of December 31, 2020.

To address the material weaknesses set forth in items (1) and (2) discussed above, management performed additional analyses and other procedures to ensure that the financial statements included herein fairly present, in all material respects, our financial position, results of operations and cash flows for the periods presented.

This Report does not include an attestation report of the Company’s independent registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by the Company’s independent registered public accounting firm pursuant to the rules of the SEC that permit the Company to provide only the management’s report in this Report.

Management’s Remediation Initiatives

In response to the above identified weaknesses in our internal control over financial reporting, we plan to work on documenting in writing our internal control policies and procedures and implement sufficient segregation of duties within our accounting functions, so that one person cannot initiate, authorize and execute transactions, and so that one person cannot record transactions in the accounting records without sufficient review by a separate person. We do not have a specific timeline within which we expect to conclude these remediation initiatives but do expect it to be an on-going process for the foreseeable future. We continue to evaluate testing of our internal control policies and procedures, including assessing internal and external resources that may be available to complete these tasks, but do not know when these tasks will be completed.

Our CEO and CFO, along with other Board members, are and will be active participants in these remediation processes. We believe the steps taken to date have improved the effectiveness of our internal control over financial reporting.

Changes in internal control over financial reporting.

There have been no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15 (f) under the Exchange Act) during the fourth quarter of our fiscal year 2019 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

On or about June 29, 2020, the Company received notice that Hanover Hoffman Estates, LLC (“HHE”), filed case number 2020L006092 in the Circuit Court of Cook County alleging failure to pay Base Rent and abandonment of certain office space in Hoffman Estates, Illinois subject to a Commercial Lease dated May 26, 2016. HHE seeks at least $672,888 in base rent and other amounts under the lease, as well as treble damages from our ex-CEO and two past Directors who were serving on our Board as of the date of the lease. The Company has continued evaluation of the allegations, defenses and alternate actions, and it is engaged settlement negotiations which are on-going.

Item 1A. Risk Factors

Not required for smaller reporting companies.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None

Item 6. Exhibits

Exhibit No.		Description
31.1		Certification of Principal Executive Officer Pursuant to Rule 13a-14*
31.2		Certification of Principal Financial Officer Pursuant to Rule 13a-14*
32.1		CEO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act*
32.2		CFO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act*
101.INS		XBRL Instance Document**
101.SCH		XBRL Taxonomy Extension Schema**
101.CAL		XBRL Taxonomy Extension Calculation Linkbase**
101.DEF		XBRL Taxonomy Extension Definition Linkbase**
101.LAB		XBRL Taxonomy Extension Label Linkbase**
101.PRE		XBRL Taxonomy Extension Presentation Linkbase**

* Filed herewith.

**Pursuant to Rule 406T of Regulation S-T, these interactive data files are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933 or Section 18 of the Securities Exchange Act of 1934 and otherwise are not subject to liability.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, there unto duly authorized.

	WELLNESS CENTER USA, INC.

Date: April 7, 2021	By:	/s/ Paul D. Jones
		Paul D. Jones
		President
		(Duly Authorized Principal Executive Officer)

	WELLNESS CENTER USA, INC.

Date: April 7, 2021	By:	/s/ Douglas W. Samuelson
		Douglas W. Samuelson
		Chief Financial Officer and Principal Accounting Officer
		(Duly Authorized Principal Accounting Officer)

POWER OF ATTORNEY

Each person whose signature appears below hereby constitutes and appoints severally Paul D. Jones, his true and lawful attorney-in-fact and agent, with full power of substitution and re-substitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, and hereby grants to such attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

SIGNATURE	TITLE	DATE

/s/ Calvin O’Harrow	Chief Executive Officer, Director	April 7, 2021
Calvin O’Harrow

/s/ Douglas W. Samuelson	Chief Financial Officer and Principal Accounting Officer	April 7, 2021
Douglas W. Samuelson

/s/ Paul D. Jones	Director, President	April 7, 2021
Paul D. Jones

/s/ Thomas E. Scott	Director, Secretary	April 7, 2021
Thomas E. Scott

/s/ William E. Kingsford	Director	April 7, 2021
William E. Kingsford

/s/ Roy M. Harsch	Director, Chairman	April 7, 2021
Roy M. Harsch

EX-31.1 2 ex31-1.htm

Exhibit 31.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Calvin O’Harrow, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Wellness Center USA, Inc. for the quarterly period ended December 31, 2020;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such internal control over financial reporting to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, if any, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period cover by this report based on such evaluation; and

d) disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting;

Date: April 7, 2021

/s/ Calvin O’Harrow
Name:	Calvin O’Harrow
Title:	Chief Executive Officer and Director

EX-31.2 3 ex31-2.htm

Exhibit 31.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Douglas W. Samuelson, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Wellness Center USA, Inc. for the quarterly period ended December 31, 2020;

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting;

Date: April 7, 2021

/s/ Douglas W. Samuelson
Name:	Douglas W. Samuelson
Title:	Chief Accounting Officer and Chief Financial Officer

EX-32.1 4 ex32-1.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q for the quarterly period ended December 31, 2020 of Wellness Center USA, Inc., a Nevada corporation (the “Company”), as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Calvin O’Harrow, Chief Executive Officer and Director of the Company, certify, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of Section 13(a) or15(d) of the Securities and Exchange Act of 1934, as amended; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

Date: April 7, 2021

/s/ Calvin O’Harrow
Name:	Calvin O’Harrow
Title:	Chief Executive Officer and Director

EX-32.2 5 ex32-2.htm

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q for the quarterly period ended December 31, 2020 of Wellness Center USA, Inc., a Nevada corporation (the “Company”), as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Douglas W. Samuelson, Chief Accounting Officer and Chief Financial Officer of the Company certify, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1. The Report fully complies with the requirements of Section 13(a) or15(d) of the Securities and Exchange Act of 1934, as amended; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

Date: April 7, 2021

/s/ Douglas W. Samuelson
Name:	Douglas W. Samuelson
Title:	Chief Accounting Officer and Chief Financial Officer

EX-101.INS 6 wcui-20201231.xml XBRL INSTANCE FILE 0001516887 2020-10-01 2020-12-31 0001516887 WCUI:TwoThousandTenNonQualifiedStockOptionPlanMember 2018-01-02 0001516887 us-gaap:CorporateMember 2019-10-01 2019-12-31 0001516887 WCUI:MedicalDevicesMember 2019-10-01 2019-12-31 0001516887 WCUI:AuthenticationandEncryptionMember 2019-10-01 2019-12-31 0001516887 WCUI:EmployeesandConsultantsMember 2018-12-01 2018-12-31 0001516887 WCUI:GEN2Member 2019-09-30 0001516887 2019-09-30 0001516887 2019-02-28 0001516887 2019-02-01 2019-02-28 0001516887 2019-10-01 2019-12-31 0001516887 us-gaap:IndividualMember 2020-04-30 0001516887 WCUI:BoardOfDirectorsMember 2020-04-01 2020-04-30 0001516887 WCUI:VestMonthlyAprilTwoThousandTwentyThroughMarchTwoThousandAndTwentyOneMember 2020-04-01 2020-04-30 0001516887 WCUI:VestMonthlyAprilTwoThousandTwentyThroughMarchTwoThousandAndTwentyThreeMember 2020-04-01 2020-04-30 0001516887 WCUI:VestOverTimeMember 2020-04-01 2020-04-30 0001516887 WCUI:ProtecScientificIncMember 2020-05-01 2020-05-31 0001516887 WCUI:HanoverHoffmanEstatesLLCMember 2020-06-28 2020-06-29 0001516887 2020-09-30 0001516887 us-gaap:CorporateMember 2020-12-31 0001516887 WCUI:MedicalDevicesMember 2020-12-31 0001516887 WCUI:AuthenticationandEncryptionMember 2020-12-31 0001516887 us-gaap:CorporateMember 2020-10-01 2020-12-31 0001516887 WCUI:MedicalDevicesMember 2020-10-01 2020-12-31 0001516887 WCUI:AuthenticationandEncryptionMember 2020-10-01 2020-12-31 0001516887 WCUI:ExEmployeeMember 2020-10-01 2020-12-31 0001516887 WCUI:TwoThousandTenNonQualifiedStockOptionPlanMember 2017-12-29 0001516887 srt:MinimumMember 2020-10-01 2020-12-31 0001516887 srt:MaximumMember 2020-10-01 2020-12-31 0001516887 srt:MinimumMember 2020-09-30 0001516887 srt:MaximumMember 2020-09-30 0001516887 WCUI:ExercisePriceRangeOneMember 2020-10-01 2020-12-31 0001516887 WCUI:ExercisePriceRangeOneMember 2020-12-31 0001516887 WCUI:ExercisePriceRangeTwoMember 2020-10-01 2020-12-31 0001516887 WCUI:ExercisePriceRangeTwoMember 2020-12-31 0001516887 us-gaap:WarrantMember 2020-09-30 0001516887 us-gaap:WarrantMember srt:MinimumMember 2020-10-01 2020-12-31 0001516887 us-gaap:WarrantMember srt:MinimumMember 2020-09-30 0001516887 us-gaap:WarrantMember srt:MaximumMember 2020-10-01 2020-12-31 0001516887 us-gaap:WarrantMember srt:MaximumMember 2020-09-30 0001516887 us-gaap:WarrantMember WCUI:ExercisePriceRangeTwoMember 2020-09-30 0001516887 WCUI:StockOptionsMember 2020-10-01 2020-12-31 0001516887 WCUI:StockOptionsMember 2019-10-01 2019-12-31 0001516887 WCUI:WarrantsMember 2020-10-01 2020-12-31 0001516887 WCUI:WarrantsMember 2019-10-01 2019-12-31 0001516887 WCUI:PsoriaShieldIncMember 2020-10-01 2020-12-31 0001516887 WCUI:PsoriaShieldIncMember 2019-09-30 0001516887 WCUI:StealthCoIncMember 2020-10-01 2020-12-31 0001516887 WCUI:StealthCoIncMember 2019-09-30 0001516887 WCUI:StealthCoIncMember 2020-09-30 0001516887 WCUI:PsoriaDevelopmentCompanyLLCMember 2020-10-01 2020-12-31 0001516887 WCUI:PsoriaDevelopmentCompanyLLCMember 2019-09-30 0001516887 WCUI:PsoriaDevelopmentCompanyLLCMember 2020-09-30 0001516887 WCUI:NeoPhototherapyLLCMember 2020-10-01 2020-12-31 0001516887 WCUI:NeoPhototherapyLLCMember 2019-09-30 0001516887 WCUI:NeoPhototherapyLLCMember 2020-09-30 0001516887 WCUI:ProtecScientificIncMember 2019-09-30 0001516887 WCUI:ProtecScientificIncMember 2020-09-30 0001516887 2018-12-01 2018-12-31 0001516887 WCUI:AprilTwentyTwoThousandTwentyMember 2020-10-01 2020-12-31 0001516887 WCUI:AprilTwentyTwoThousandTwentyMember 2020-12-31 0001516887 WCUI:FormerCEOMember 2020-10-01 2020-12-31 0001516887 2020-12-31 0001516887 2019-12-31 0001516887 WCUI:PsoriaShieldIncMember 2020-09-30 0001516887 WCUI:ProtecScientificIncMember 2020-10-01 2020-12-31 0001516887 us-gaap:RestrictedStockMember 2020-10-01 2020-12-31 0001516887 us-gaap:RestrictedStockMember 2020-12-31 0001516887 us-gaap:StockOptionMember 2020-10-01 2020-12-31 0001516887 us-gaap:StockOptionMember 2020-12-31 0001516887 us-gaap:StockOptionMember WCUI:TwoThousandTenPlanMember 2020-12-31 0001516887 us-gaap:WarrantMember 2020-12-31 0001516887 srt:MinimumMember 2020-12-31 0001516887 srt:MaximumMember 2020-12-31 0001516887 us-gaap:WarrantMember 2020-10-01 2020-12-31 0001516887 us-gaap:WarrantMember srt:MinimumMember 2020-12-31 0001516887 us-gaap:WarrantMember srt:MaximumMember 2020-12-31 0001516887 us-gaap:WarrantMember WCUI:ExercisePriceRangeOneMember 2020-10-01 2020-12-31 0001516887 us-gaap:WarrantMember WCUI:ExercisePriceRangeOneMember 2020-12-31 0001516887 us-gaap:WarrantMember WCUI:ExercisePriceRangeTwoMember 2020-10-01 2020-12-31 0001516887 us-gaap:WarrantMember WCUI:ExercisePriceRangeTwoMember 2020-12-31 0001516887 us-gaap:SubsequentEventMember 2021-04-07 0001516887 us-gaap:SubsequentEventMember WCUI:BoardOfDirectorsMember WCUI:AprilTwoThousandTwentyThreeThroughMarchTwoThousandTwentyFourMember 2021-03-29 2021-04-01 0001516887 us-gaap:SubsequentEventMember WCUI:OfficersandDirectorsMember WCUI:AprilTwoThousandTwentyFiveMember 2021-03-29 2021-04-01 0001516887 us-gaap:SubsequentEventMember WCUI:OfficersandDirectorsMember 2021-03-29 2021-04-01 0001516887 us-gaap:SubsequentEventMember WCUI:CEOMember WCUI:AprilTwoThousandTwentyThreeThroughMarchTwoThousandTwentyFourMember 2021-03-29 2021-04-01 0001516887 us-gaap:SubsequentEventMember WCUI:CEOMember WCUI:AprilTwoThousandTwentyThreeThroughMarchTwoThousandTwentyFourMember 2021-04-01 0001516887 us-gaap:SubsequentEventMember WCUI:CEOMember 2021-03-29 2021-04-01 0001516887 us-gaap:SubsequentEventMember WCUI:CEOMember 2021-04-01 0001516887 us-gaap:SubsequentEventMember WCUI:CEOMember WCUI:AprilTwoThousandTwentyFiveMember 2021-03-29 2021-04-01 0001516887 us-gaap:SubsequentEventMember WCUI:CEOMember WCUI:SeptemberTwoThousandTwentyOneThroughDecemberTwoThousandTwentyOneMember 2021-03-29 2021-04-01 0001516887 us-gaap:CommonStockMember 2019-10-01 2019-12-31 0001516887 us-gaap:CommonStockMember 2019-09-30 0001516887 us-gaap:CommonStockMember 2019-12-31 0001516887 us-gaap:AdditionalPaidInCapitalMember 2019-10-01 2019-12-31 0001516887 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001516887 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001516887 us-gaap:RetainedEarningsMember 2019-10-01 2019-12-31 0001516887 us-gaap:RetainedEarningsMember 2019-09-30 0001516887 us-gaap:RetainedEarningsMember 2019-12-31 0001516887 WCUI:TotalWCUIDeficitMember 2019-10-01 2019-12-31 0001516887 WCUI:TotalWCUIDeficitMember 2019-09-30 0001516887 WCUI:TotalWCUIDeficitMember 2019-12-31 0001516887 us-gaap:NoncontrollingInterestMember 2019-10-01 2019-12-31 0001516887 us-gaap:NoncontrollingInterestMember 2019-09-30 0001516887 us-gaap:NoncontrollingInterestMember 2019-12-31 0001516887 us-gaap:CommonStockMember 2020-10-01 2020-12-31 0001516887 us-gaap:CommonStockMember 2020-09-30 0001516887 us-gaap:CommonStockMember 2020-12-31 0001516887 us-gaap:AdditionalPaidInCapitalMember 2020-10-01 2020-12-31 0001516887 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001516887 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001516887 us-gaap:RetainedEarningsMember 2020-10-01 2020-12-31 0001516887 us-gaap:RetainedEarningsMember 2020-09-30 0001516887 us-gaap:RetainedEarningsMember 2020-12-31 0001516887 WCUI:TotalWCUIDeficitMember 2020-10-01 2020-12-31 0001516887 WCUI:TotalWCUIDeficitMember 2020-09-30 0001516887 WCUI:TotalWCUIDeficitMember 2020-12-31 0001516887 us-gaap:NoncontrollingInterestMember 2020-10-01 2020-12-31 0001516887 us-gaap:NoncontrollingInterestMember 2020-09-30 0001516887 us-gaap:NoncontrollingInterestMember 2020-12-31 0001516887 WCUI:PsoriaShieldIncMember 2018-12-31 0001516887 WCUI:GenTwoFundingIncMember 2018-12-31 0001516887 WCUI:ProtecScientificIncMember WCUI:NonAffiliatedInvestorsMember 2020-09-30 0001516887 WCUI:ProtecScientificIncMember 2020-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure Wellness Center USA, Inc. 0001516887 10-Q 2020-12-31 false --09-30 Non-accelerated Filer Q1

51320

8178

67709

2636

78523

181950

45600

74202

38348

0.001

30000000

200000000

7500000

200000000

118252077

119639577

118252077

119639577

10399

308541

98462

175286

63525

337273

49109

256471

2961

-298142

-98462

-175286

-63525

-337273

-49109

-246072

-2961

151433

101492

-26158

-9323

-143602

-22129

-180698

-324467

-0.00

1562

41625

500

-267797

-195784

295000

185000

295000

135000

25053616

74400

25104736

191000

120000

80100

true false

146380

8678

226220

2636

237534

6961

1613

153341

8678

227833

2636

239147

119639577 10882 65738 Yes Yes false

90499

2021

500

27203

-10784

53147

51320

78523

42363

72447

84012

-50000

118960909

107497077

6961

1613

-5348 -5144 27841

27841

6961

1613

94560

134522

-4500

89962

-2229545

-2501338

-1314852

107497

23777647

23868885

-25362287

-25686754

-1477143

-1710372

393149

395520

118252

119639

25053616

25104736

-27583363

-27764061

-2411495

-2539686

181950

38348

-324300

-346596

-324467

-22129

-180698

-143602

5348

672878

0.04

21600

179548

0.02 0.02

NOTE 3 – LOANS PAYABLE FROM OFFICERS AND SHAREHOLDERS   As of September 30, 2020, loans payable from officers and shareholders of $1,165,250 were outstanding. During the three months ended December 31, 2020, the Company borrowed $295,000 from its officers and shareholders. All of the loans are unsecured, have an interest rate of eight percent and are due one year from the date of issuance. As of December 31, 2020, loans payable to officers and shareholders of $1,460,250 were outstanding and $504,250 was past due.

NOTE 4 – U.S. SMALL BUSINESS ADMINISTRATION LOAN PAYABLE   During the year ended September 30, 2020, the Company’s subsidiary, PSI, entered into a loan agreement with the United States Small Business Administration (SBA) under which the Company borrowed $37,166. The loan is unsecured, accrues interest at 1.0% and is due on April 23, 2022. Beginning in March 2021, PSI is required to make monthly interest payments and all principal and unpaid interest is due in April 2022. If PSI meets certain criteria as defined in the agreement, the loan may be forgiven at which time the Company would recognize a gain on debt forgiveness. As of the date of this filing, the Company had not yet applied for forgiveness of the loan. As of December 31, 2020, a total of $37,166 was outstanding on the loan.

NOTE 7 – SEGMENT REPORTING   Reportable segments are components of an enterprise about which separate financial information is available and that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. The Company’s reportable segments are based on products and services, geography, legal structure, management structure, or any other manner in which management disaggregates a company.   The Company operates in the following business segments:   (i) Medical Devices: which stems from PSI, its wholly-owned subsidiary acquired on August 24, 2012, a developer, manufacturer, marketer and distributer of targeted Ultra Violet (“UV”) phototherapy devices for the treatment of skin diseases, and for sanitation purposes.   (ii) Authentication and Encryption Products and Services: which stems from StealthCo, its wholly-owned subsidiary formed on March 18, 2014, which has engaged in the business of selling, licensing or otherwise providing certain authentication and encryption products and services since acquisition of certain assets from SMI on April 4, 2014.   The detailed segment information of the Company is as follows:   Assets By Segment   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center">December 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Corporate</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Medical Devices</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Authentication and Encryption</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: center">ASSETS</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Current Assets</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 51%">Cash</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">8,178</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">67,709</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">2,636</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">78,523</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Accounts receivable</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">23,989</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">23,989</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Inventories</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">134,522</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">134,522</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Prepaid expenses and other current assets</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">500</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">500</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Total current assets</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">8,678</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">226,220</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">2,636</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">237,534</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Right of use asset</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,613</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,613</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Total other assets</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,613</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,613</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">TOTAL ASSETS</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">8,678</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">227,833</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">2,636</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">239,147</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>   Operations by Segment   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="14" style="text-align: center">For the Three Months Ended</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center">December 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Corporate</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Medical Devices</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Authentication and Encryption</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 51%">Trade sales</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">90,499</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">90,499</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Cost of goods sold</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">80,100</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">80,100</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Gross profit</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">10,399</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">10,399</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Operating expenses</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">49,109</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">256,471</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">2,961</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">308,541</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Loss from operations</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(49,109</td> <td style="padding-bottom: 2.5pt">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(246,072</td> <td style="padding-bottom: 2.5pt">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(2,961</td> <td style="padding-bottom: 2.5pt">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(298,142</td> <td style="padding-bottom: 2.5pt">)</td></tr> </table>    <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="14" style="text-align: center">For the Three Months Ended</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center">December 31, 2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Corporate</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Medical Devices</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Authentication and Encryption</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 51%">Trade sales</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">-</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Cost of goods sold</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Gross profit</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Operating expenses</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">98,462</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">175,286</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">63,525</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">337,273</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Loss from operations</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(98,462</td> <td style="padding-bottom: 2.5pt">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(175,286</td> <td style="padding-bottom: 2.5pt">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(63,525</td> <td style="padding-bottom: 2.5pt">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(337,273</td> <td style="padding-bottom: 2.5pt">)</td></tr> </table>

NOTE 8 – LEGAL MATTERS   The Company is periodically engaged in legal proceedings arising from and relating to its business operations. Except as otherwise described herein, we currently are not involved in any litigation that we believe could have a material adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body pending or, to the knowledge of the executive officers of our Company or any of our subsidiaries, threatened against or affecting our Company, our common stock, any of our subsidiaries or of our Company’s or our subsidiaries’ officers or directors in their capacities as such, in which an adverse decision could have a material adverse effect on our financial condition or results of operations.   We continue efforts to preserve revenue and reduce operating expenses through actions including, but not limited to, facilities consolidation and staff reductions, which we hope to implement through negotiated transactions with lessors, employees and other third parties. Such actions may result in disputes with and claims by such parties which, if not resolved through negotiations, may impact negatively the Company’s ability to continue as a going concern. To date, the Company has negotiated settlement of all ex-employee wage and benefits claims except for two. The first regards unpaid wages claimed due together with interest at the rate of 4% per annum on such amount as the Company originally agreed upon in settlement negotiations. The ex-employee claims additional amounts due for certain statutory damages under the Illinois Wage Payment and Collection which currently could exceed $21,600.00 and would increase at the rate of 2% of the wages due per month plus attorneys’ fees if the employee elects to file suit for a violation of the Act and is successful in obtaining a judgment on his claim.   The second claim was filed with the Illinois Department of Labor asserting a violation of the Illinois Wage Payment and Collection Act by the Company’s former CEO. That claim alleges unpaid wages in the amount of $158,714.60 and unpaid vacation pay in the amount of $20,833.33 for a total amount of $179,547.90, as well as certain statutory damages including, but not limited to, 2% of the wages due per month plus attorneys’ fees if the ex-CEO elects to file suit for a violation of the Act and is successful in obtaining a judgment on his claim. The Company has filed its response to such claim with the Department denying the substantive allegations therein and asserting certain factual and legal defenses, including breach of fiduciary duty, as a bar to all claimed compensation. The claim remains pending, but as the date hereof, no suit has been filed against the Company asserting a violation of the Act based on said claim.

Basis of Consolidation   The consolidated financial statements include the Company’s wholly owned subsidiaries and the accounts of its subsidiaries for which it was determined that Company has operational and management control. The Company’s consolidated subsidiaries and/or controlled entities are as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center">Name of consolidated subsidiary or entity</td> <td style="text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">State or other jurisdiction of incorporation or organization</td> <td style="text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">Date of incorporation or formation (date of acquisition/disposition, if applicable)</td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Attributable interest at September 30, 2019</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Attributable interest at September 30, 2020</td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 27%">Psoria-Shield Inc. (“PSI”)</td> <td style="width: 2%"> </td> <td style="width: 17%; text-align: center">The State of Florida</td> <td style="width: 2%"> </td> <td style="width: 17%"> June 2009 (August 2012)</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 12%; text-align: right">100</td> <td style="width: 3%">%</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 12%; text-align: right">51</td> <td style="width: 3%">%(1)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>StealthCo, Inc. (“StealthCo”)</td> <td> </td> <td style="text-align: center">The State of Illinois</td> <td> </td> <td style="text-align: center">March 2014</td> <td> </td> <td> </td> <td style="text-align: right">100</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">100</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Psoria Development Company LLC. (“PDC”)</td> <td> </td> <td style="text-align: center">The State of Illinois</td> <td> </td> <td> January 2015/ November 2018</td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>NEO Phototherapy LLC (“NEO”)</td> <td> </td> <td style="text-align: center">The State of Illinois</td> <td> </td> <td style="text-align: center">December 2018</td> <td> </td> <td> </td> <td style="text-align: right">51</td> <td>%(1)</td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Protec Scientific, Inc (“Protec”)</td> <td> </td> <td style="text-align: center">The State of New York</td> <td> </td> <td style="text-align: center">April 2020</td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">38</td> <td>%</td></tr> </table>   (1) - Effective April 30, 2020, the Company’s 51% interest in NEO was converted into a 51% interest in PSI.

Use of Estimates   The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date, and reported amounts of revenue and expenses during the reporting period. Significant estimates are used in the valuation of accounts receivable and allowance for uncollectible amounts, inventory and obsolescence reserves, accruals for potential liabilities, valuations of stock-based compensation, and realization of deferred tax assets, among others. Actual results could differ from these estimates.

Income (Loss) Per Share   Basic loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of outstanding common shares during the period. Diluted loss per share is computed by dividing the net loss applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. For the three months ended December 31, 2020 and 2019, the basic and diluted shares outstanding were the same, as potentially dilutive shares were considered anti-dilutive. At December 31, 2020 and 2019, the dilutive impact of outstanding stock options of 12,665,238 and 15,037,738 shares, respectively, and outstanding warrants for 67,634,049 and 66,484,049 shares, respectively, have been excluded because their impact on the loss per share is anti-dilutive.

Revenue Recognition   The company records revenue under the guidance of Accounting Standards Codification (“ASC“) 606, Revenue from Contracts with Customers (Topic 606) which requires a company to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services.   For trade sales, the Company generates its revenue from sales contracts with customers with revenues being generated upon the shipment of merchandise, or for consulting services, revenue is recognized in the period services are rendered and earned under service arrangements with clients.   We sell our products through two main sales channels: 1) directly to customers who use our products (the “Direct Channel”) and 2) to distribution partners who resell our products (the “Indirect Channel”).   Under the Direct Channel, we sell our products to and we receive payment directly from customers who purchase our products. Under our Indirect Channel, we have entered into distribution agreements that allow the distributors to sell our products and fulfill performance obligations under the agreements.   We determine revenue recognition through the following steps:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 48px">●</td> <td>Identification of the contract, or contracts, with a customer</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>●</td> <td>Identification of the performance obligations in the contract</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>●</td> <td>Determination of the transaction price</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>●</td> <td>Allocation of the transaction price to the performance obligations in the contract</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>●</td> <td>Recognition of revenue when, or as, we satisfy a performance obligation.</td></tr> </table>   Revenue is generally recognized upon shipment or when a service has been completed, unless we have significant performance obligations for services still to be completed. We recognize revenue when a material reversal is no longer probable. Payments received before the relevant criteria for revenue recognition are satisfied are recorded as deferred revenue. There was no deferred revenue at December 31, 2020 and 2019.

Non-controlling Interests   In December 2018, PSI entered into a Joint Venture Agreement with GEN2 for further development, marketing, licensing and/or sale of PSI technology and products. Pursuant to the Joint Venture Agreement, the venture will be conducted through NEO Phototherapy, Inc. (“NEO”). PSI and GEN2 will be the members of NEO, owning 50.5% and 36.0%, respectively, of the Units issued in connection with the organization of NEO. An additional 13.5% of such Units will be reserved for issuance as incentives for key employees and consultants. As of September 30, 2019, GEN2 had received $975,000 of investments to contribute to NEO. As of April 30, 2020, the Company controlled 51% of the joint venture, GEN2 controlled 39% and another individual controlled the remaining 10%.   Effective April 30, 2020, the joint venture with GEN2 was reorganized. GEN2 shareholders exchanged their common shares in GEN2, and the individual exchanged his membership interests in NEO, for common shares representing 49% ownership in PSI. The Company retained its common shares in PSI, which provides the Company a 51% economic interest in the PSI technology and products developed by the joint venture. During three months ended December 31, 2020, PSI recorded a loss of $151,433 relating to its operations, of which $74,202 was allocated to the non-controlling interest.   Repayment of the $975,000 investment will begin through and upon the date which PSI has realized and retained cumulative net income/distributable cash in the amount of $300,000. The minority interest of PSI ownership consists of accredited investors, and investment participation of $750,000 from several WCUI officers and directors, including Calvin R. O’Harrow and Roy M. Harsch.   In May 2020, the Company’s subsidiary, PSI, agreed to become a majority shareholder in Protec Scientific, Inc. (“Protec”), a company formed in April 2020 by John Yorke for the purpose of designing, developing and marketing products that use spectral photonic emissions across a variety of applications. As of September 30, 2020, PSI had advanced $191,000 to Protec in furtherance of its agreement to acquire approximately 62% of Protec, with the Company’s share being approximately 32%, based on its PSI ownership. The remaining 30% share is to be attributed to PSI’s minority shareholders, based on their PSI ownership. During the year ended September 30, 2020, Protec received an additional $120,000 from non-affiliated investors, of which $74,400 was recorded to additional paid-in capital and $45,600 to the non-controlling interests. The additional investments gave the non-controlling interests a 38% ownership interest in Protec. During the three months ended December 31, 2020, Protec recorded a loss of $101,492, of which $69,400 was allocated to the non-controlling interests.

Stock-Based Compensation   The Company periodically issues stock-based compensation to officers, directors, and consultants for services rendered, and as part of financing transactions. Such issuances vest and expire according to terms established at the issuance date. Stock-based payments to officers, directors, employees, and for acquiring goods and services from non-employees, which include grants of employee stock options, are recognized in the financial statements based on their fair values in accordance with Topic 718. Stock option grants, which are generally time vested, will be measured at the grant date fair value and charged to operations on a straight-line basis over the vesting period.   The fair value of the Company’s common stock option and warrant grants are estimated using a Black-Scholes Merton option pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the common stock options, estimated forfeitures and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes option pricing model, and based on actual experience. The assumptions used in the Black-Scholes Merton option pricing model could materially affect compensation expense recorded in future periods.

Recently Issued Accounting Pronouncements   In June 2016, the FASB issued ASU No. 2016-13, Credit Losses - Measurement of Credit Losses on Financial Instruments (“ASC 326”). The standard significantly changes how entities will measure credit losses for most financial assets, including accounts and notes receivables. The standard will replace today’s “incurred loss” approach with an “expected loss” model, under which companies will recognize allowances based on expected rather than incurred losses. Entities will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The standard is effective for interim and annual reporting periods beginning after December 15, 2019. The adoption of ASU 2016-13 is not expected to have a material impact on the Company’s financial position, results of operations, and cash flows.   Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

The Company’s consolidated subsidiaries and/or controlled entities are as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center">Name of consolidated subsidiary or entity</td> <td style="text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">State or other jurisdiction of incorporation or organization</td> <td style="text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">Date of incorporation or formation (date of acquisition/disposition, if applicable)</td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Attributable interest at September 30, 2019</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Attributable interest at September 30, 2020</td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 27%">Psoria-Shield Inc. (“PSI”)</td> <td style="width: 2%"> </td> <td style="width: 17%; text-align: center">The State of Florida</td> <td style="width: 2%"> </td> <td style="width: 17%"> June 2009 (August 2012)</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 12%; text-align: right">100</td> <td style="width: 3%">%</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 12%; text-align: right">51</td> <td style="width: 3%">%(1)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>StealthCo, Inc. (“StealthCo”)</td> <td> </td> <td style="text-align: center">The State of Illinois</td> <td> </td> <td style="text-align: center">March 2014</td> <td> </td> <td> </td> <td style="text-align: right">100</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">100</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Psoria Development Company LLC. (“PDC”)</td> <td> </td> <td style="text-align: center">The State of Illinois</td> <td> </td> <td> January 2015/ November 2018</td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>NEO Phototherapy LLC (“NEO”)</td> <td> </td> <td style="text-align: center">The State of Illinois</td> <td> </td> <td style="text-align: center">December 2018</td> <td> </td> <td> </td> <td style="text-align: right">51</td> <td>%(1)</td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Protec Scientific, Inc (“Protec”)</td> <td> </td> <td style="text-align: center">The State of New York</td> <td> </td> <td style="text-align: center">April 2020</td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">38</td> <td>%</td></tr> </table>   (1) - Effective April 30, 2020, the Company’s 51% interest in NEO was converted into a 51% interest in PSI.

The following table summarizes restricted common stock activity:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Number of Restricted Shares</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Fair Value</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Weighted Average Grant Date Fair Value</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 49%">Non-vested, September 30, 2020</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">10,275,000</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">308,250</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">0.03</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Vested</td> <td> </td> <td> </td> <td style="text-align: right">(1,387,500</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">(41,625</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">0.03</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Forfeited</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Non-vested, December 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">8,887,500</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">266,625</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.03</td> <td style="padding-bottom: 1.5pt"> </td></tr> </table>

The table below summarizes the Company’s stock option activities for the three months ended December 31, 2020:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Number of Option Shares</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Exercise Price Range Per Share</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 49%">Balance, September 30, 2020</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">14,127,738</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">0.03 - 2.00</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">0.29</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Cancelled</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Exercised</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Expired</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(1,462,500</td> <td style="padding-bottom: 1.5pt">)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.14 - 2.00</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1.41</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">Balance, December 31, 2020</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">12,665,238</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.03 - 0.40</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.10</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Vested and exercisable, December 31, 2020</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">9,702,738</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.03 - 0.40</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.12</td> <td style="padding-bottom: 2.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Unvested, December 31, 2020</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">2,962,500</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.04</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.04</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

The following table summarizes information concerning outstanding and exercisable options as of December 31, 2020:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center">Options Outstanding</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center">Options Exercisable</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1.5pt solid">Range of Exercise Prices</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Number Outstanding</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Average Remaining Contractual Life (in years)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Number Exercisable</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Average Remaining Contractual Life (in years)</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 1%">$</td> <td style="width: 17%; text-align: right">0.03 - 0.39</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">12,602,738</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">6.75</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">0.09</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">9,640,238</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 10%; text-align: right">5.85</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 10%; text-align: right">0.12</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.40</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">62,500</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1.25</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.40</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">62,500</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1.25</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.40</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.03 - 0.40</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">12,665,238</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6.72</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.10</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">9,702,738</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">5.82</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.12</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

The table below summarizes the Company’s warrants activities for the three months ended December 31, 2020:   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Number of Warrant Shares</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Exercise Price Range Per Share</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td style="padding-bottom: 1.5pt; text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td> <td style="padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 49%">Balance, September 30, 2020</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">67,634,049</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">0.07 - 0.40</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 14%; text-align: right">0.16</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Cancelled</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Exercised</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Expired</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Balance, December 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">67,634,049</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.07 - 0.40</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.16</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Vested and exercisable, December 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">67,634,049</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.07 - 0.40</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.16</td> <td style="padding-bottom: 1.5pt"> </td></tr> </table>

The following table summarizes information concerning outstanding and exercisable warrants as of December 31, 2020:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center">Warrants Outstanding</td> <td> </td> <td> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center">Warrants Exercisable</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1.5pt solid">Range of Exercise Prices</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Number Outstanding</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Average Remaining Contractual Life (in years)</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Number Exercisable</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Average Remaining Contractual Life (in years)</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 1%">$</td> <td style="width: 17%; text-align: right">0.12 – 0.20</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">60,429,384</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">1.74</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">0.15</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">60,429,384</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">1.74</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">0.15</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"> 0.21 – 0.40</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">7,204,665</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.64</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.26</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">7,204,665</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.64</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.26</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.12 – 0.67</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">67,634,049</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1.62</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.16</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">67,634,049</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1.62</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.16</td> <td> </td></tr> </table>

The detailed segment information of the Company is as follows:   Assets By Segment   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center">December 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Corporate</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Medical Devices</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Authentication and Encryption</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: center">ASSETS</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Current Assets</td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 51%">Cash</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">8,178</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">67,709</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">2,636</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">78,523</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Accounts receivable</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">23,989</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">23,989</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Inventories</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">134,522</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">134,522</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Prepaid expenses and other current assets</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">500</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">500</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Total current assets</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">8,678</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">226,220</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">2,636</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">237,534</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Right of use asset</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,613</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,613</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt">Total other assets</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,613</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1,613</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 2.5pt">TOTAL ASSETS</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">8,678</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">227,833</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">2,636</td> <td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">239,147</td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>

7120000

1800000

11250000

13050000

1387500

3025714

7060000

9052500

4396929

1300000

13449429

P5Y9M25D

P5Y10M6D

P1Y2M30D

41625

10882

266625

85882

10275000

8887500

1387500

308250

266625

41625

0.03

14127738

12602738

62500

12665238

17334762

5277778

1462500

9702738

2962500

0.29

0.09

0.40

0.10

1.41

0.12

0.04

0.03

0.40

0.39

0.40

P6Y8M19D

P6Y9M

P1Y2M30D

9640238

62500

9702738

0.12

0.40

0.12

67634049

60429384

7204665

67634049 60429384 7204665 0.16 0.07 0.40 0.16 0.07 0.40 0.07 0.40 0.16

Operations by Segment   <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="14" style="text-align: center">For the Three Months Ended</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center">December 31, 2020</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Corporate</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Medical Devices</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Authentication and Encryption</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 51%">Trade sales</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">90,499</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">90,499</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Cost of goods sold</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">80,100</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">80,100</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Gross profit</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">10,399</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">10,399</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Operating expenses</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">49,109</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">256,471</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">2,961</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">308,541</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Loss from operations</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(49,109</td> <td style="padding-bottom: 2.5pt">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(246,072</td> <td style="padding-bottom: 2.5pt">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(2,961</td> <td style="padding-bottom: 2.5pt">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(298,142</td> <td style="padding-bottom: 2.5pt">)</td></tr> </table>    <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="14" style="text-align: center">For the Three Months Ended</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="14" style="border-bottom: black 1.5pt solid; text-align: center">December 31, 2019</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Corporate</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Medical Devices</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Authentication and Encryption</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Total</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 51%">Trade sales</td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">-</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">-</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Cost of goods sold</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Gross profit</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 1.5pt">Operating expenses</td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">98,462</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">175,286</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">63,525</td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">337,273</td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt">Loss from operations</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(98,462</td> <td style="padding-bottom: 2.5pt">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(175,286</td> <td style="padding-bottom: 2.5pt">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(63,525</td> <td style="padding-bottom: 2.5pt">)</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">(337,273</td> <td style="padding-bottom: 2.5pt">)</td></tr> </table>

Nevada The State of Florida The State of Illinois The State of Illinois The State of Illinois The State of New York

12665238

15037738

67634049

66484049

50000

0.49

0.505

0.360

0.135

Pursuant to the Joint Venture Agreement, the venture will be conducted through NEO Phototherapy, Inc. ("NEO"). PSI and GEN2 will be the members of NEO, owning 50.5% and 36.0%, respectively, of the Units issued in connection with the organization of NEO. An additional 13.5% of such Units will be reserved for issuance as incentives for key employees and consultants. As of September 30, 2019, GEN2 had received $975,000 of investments to contribute to NEO. As of April 30, 2020, the Company controlled 51% of the joint venture, GEN2 controlled 39% and another individual controlled the remaining 10%.

The joint venture with GEN2 was reorganized. GEN2 shareholders exchanged their common shares in GEN2, and the individual exchanged his membership interests in NEO, for common shares representing 49% ownership in PSI. The Company retained its common shares in PSI, which provides the Company a 51% economic interest in the PSI technology and products developed by the joint venture. During three months ended December 31, 2020, PSI recorded a loss of $151,433 relating to its operations, of which $74,202 was allocated to the non-controlling interest.

975000

0.51

750000

In May 2020, the Company's subsidiary, PSI, agreed to become a majority shareholder in Protec Scientific, Inc. ("Protec"), a company formed in April 2020 by John Yorke for the purpose of designing, developing and marketing products that use spectral photonic emissions across a variety of applications. As of September 30, 2020, PSI had advanced $191,000 to Protec in furtherance of its agreement to acquire approximately 62% of Protec, with the Company's share being approximately 32%, based on its PSI ownership. The remaining 30% share is to be attributed to PSI's minority shareholders, based on their PSI ownership. During the year ended September 30, 2020, Protec received an additional $120,000 from non-affiliated investors, of which $74,400 was recorded to additional paid-in capital and $45,600 to the non-controlling interests. The additional investments gave the non-controlling interests a 38% ownership interest in Protec. 69400 Psoria-Shield Inc. ("PSI") StealthCo, Inc. ("StealthCo") Psoria Development Company LLC. ("PDC") NEO Phototherapy LLC ("NEO") Protec Scientific, Inc ("Protec") 2009-06 2014-03 2015-01 2018-12 2020-04 2012-08 2018-11

1.00

0.00

0.51

0.00

0.38

0.51

1165250

0.010

1460250

355000

37166

2022-04-23

Beginning in March 2021, PSI is required to make monthly interest payments and all principal and unpaid interest is due in April 2022.

P24M

5348

1850

0.0400

2021-01-31

11000

631587 975000

300000

5348

5144

20170000

3750000

10085714

158715 20833

23989

26158

9323

50000

23989

504250

295000

504250

126625

0.03

2.00

0.03

0.40

0.05

0.14 2.00 0.04 0.03 0.40 P1Y7M13D P1Y8M26D P7M21D P1Y7M13D P1Y8M26D P7M21D 0.16 0.15 0.26 0.26 0.16 0.15 0.67 0.20 0.40 0.12 0.12 0.21

187500

504286

65000

670000

408297

480744

92334

87834

672878 672878

1165250

1460250

2345720

2703319

37166

2382886

2740485

118252

119639

-27583363

-27764061

-2411495

-2539686

153341

239147

107497077

118252077

119639577

10882

65738

10882

50000

25500

24500

41625

1387

40238

41625

1387500

NOTE 1 – BASIS OF PRESENTATION   Organization and Operations   Wellness Center USA, Inc. (“WCUI” or the “Company”) was incorporated in June 2010 under the laws of the State of Nevada. The Company initially engaged in online sports and nutrition supplements marketing and distribution. The Company subsequently expanded into additional businesses within the healthcare and medical sectors through acquisitions, including Psoria-Shield Inc. (“PSI”) and StealthCo Inc. (“SCI”), d/b/a Stealth Mark, Inc.   The Company currently operates in the following business segments: (i) distribution of targeted Ultra Violet (“UV”) phototherapy devices for dermatology and sanitation purposes; and (ii) authentication and encryption products and services. The segments are operated, respectively, through PSI and SCI.   Basis of Presentation of Unaudited Financial Information   The accompanying unaudited condensed consolidated financial statements of Wellness Center USA, Inc. and Subsidiaries (the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all normal recurring adjustments considered necessary for a fair presentation have been included. Operating results for the three months ended December 31, 2020 are not necessarily indicative of the results that may be expected for the year ending September 30, 2021.   COVID-19 Considerations   In the period ended December 31, 2020, the COVID-19 pandemic did not have a material net impact on our operating results. In the future, the pandemic may cause reduced demand for our products if, for example, the pandemic results in a recessionary economic environment which negatively effects the consumers who purchase our products.   Our ability to operate without significant negative operational impact from the COVID-19 pandemic will in part depend on our ability to protect our employees and our supply chain. The Company has endeavored to follow the recommended actions of government and health authorities to protect our employees. Since the onset of the COVID-19 pandemic, we maintained the consistency of our operations. However, the uncertainty resulting from the pandemic could result in an unforeseen disruption to our workforce and supply chain (for example an inability of a key supplier or transportation supplier to source and transport materials) that could negatively impact our operations.   Through December 31, 2020, the COVID-19 pandemic has not negatively impacted the Company’s liquidity position as of such date. Through December 31, 2020, the Company continues to generate cash flows through financing activities to meet its short-term liquidity needs, and it expects to maintain access to those shareholder loans. The Company has not observed any material impairments of its assets or a significant change in the fair value of its assets due to the COVID-19 pandemic.   Going Concern   The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying condensed consolidated financial statements, the Company has not yet generated significant revenues and has incurred recurring net losses. During the three months ended December 31, 2020, the Company incurred a net loss of $324,300 and used cash in operations of $267,797, and had a shareholders’ deficit of $2,501,338 as of December 31, 2020. In addition, loans payable of $504,250 and payroll taxes of $87,834 are past due. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent upon the Company’s ability to raise additional funds and implement its strategies. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.   In addition, the Company’s independent registered public accounting firm, in its report on the Company’s September 30, 2020 financial statements, has raised substantial doubt about the Company’s ability to continue as a going concern.   At December 31, 2020, the Company had cash on hand in the amount of $78,523. The ability to continue as a going concern is dependent on the Company attaining and maintaining profitable operations in the future and raising additional capital soon to meet its obligations and repay its liabilities arising from normal business operations when they come due. Since inception, we have funded our operations primarily through equity and debt financings and we expect to continue to rely on these sources of capital in the future. During the three months ended December 31, 2020, the Company received $295,000 through short-term loans from officers and shareholders.   No assurance can be given that any future financing will be available or, if available, that it will be on terms that are satisfactory to the Company. Even if the Company is able to obtain additional financing, it may contain undue restrictions on our operations, in the case of debt financing or cause substantial dilution for our stock holders, in case of equity financing.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES   Basis of Consolidation   The consolidated financial statements include the Company’s wholly owned subsidiaries and the accounts of its subsidiaries for which it was determined that Company has operational and management control. The Company’s consolidated subsidiaries and/or controlled entities are as follows:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid; text-align: center">Name of consolidated subsidiary or entity</td> <td style="text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">State or other jurisdiction of incorporation or organization</td> <td style="text-align: center"> </td> <td style="border-bottom: black 1.5pt solid; text-align: center">Date of incorporation or formation (date of acquisition/disposition, if applicable)</td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Attributable interest at September 30, 2019</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Attributable interest at September 30, 2020</td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 27%">Psoria-Shield Inc. (“PSI”)</td> <td style="width: 2%"> </td> <td style="width: 17%; text-align: center">The State of Florida</td> <td style="width: 2%"> </td> <td style="width: 17%"> June 2009 (August 2012)</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 12%; text-align: right">100</td> <td style="width: 3%">%</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 12%; text-align: right">51</td> <td style="width: 3%">%(1)</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>StealthCo, Inc. (“StealthCo”)</td> <td> </td> <td style="text-align: center">The State of Illinois</td> <td> </td> <td style="text-align: center">March 2014</td> <td> </td> <td> </td> <td style="text-align: right">100</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">100</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Psoria Development Company LLC. (“PDC”)</td> <td> </td> <td style="text-align: center">The State of Illinois</td> <td> </td> <td> January 2015/ November 2018</td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>NEO Phototherapy LLC (“NEO”)</td> <td> </td> <td style="text-align: center">The State of Illinois</td> <td> </td> <td style="text-align: center">December 2018</td> <td> </td> <td> </td> <td style="text-align: right">51</td> <td>%(1)</td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td>%</td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Protec Scientific, Inc (“Protec”)</td> <td> </td> <td style="text-align: center">The State of New York</td> <td> </td> <td style="text-align: center">April 2020</td> <td> </td> <td> </td> <td style="text-align: right">0</td> <td>%</td> <td> </td> <td> </td> <td style="text-align: right">38</td> <td>%</td></tr> </table>   (1) - Effective April 30, 2020, the Company’s 51% interest in NEO was converted into a 51% interest in PSI.   Use of Estimates   The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the U.S requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the financial statement date, and reported amounts of revenue and expenses during the reporting period. Significant estimates are used in the valuation of accounts receivable and allowance for uncollectible amounts, inventory and obsolescence reserves, accruals for potential liabilities, valuations of stock-based compensation, and realization of deferred tax assets, among others. Actual results could differ from these estimates.   Income (Loss) Per Share   Basic loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of outstanding common shares during the period. Diluted loss per share is computed by dividing the net loss applicable to common stockholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued. For the three months ended December 31, 2020 and 2019, the basic and diluted shares outstanding were the same, as potentially dilutive shares were considered anti-dilutive. At December 31, 2020 and 2019, the dilutive impact of outstanding stock options of 12,665,238 and 15,037,738 shares, respectively, and outstanding warrants for 67,634,049 and 66,484,049 shares, respectively, have been excluded because their impact on the loss per share is anti-dilutive.   Revenue Recognition   The company records revenue under the guidance of Accounting Standards Codification (“ASC“) 606, Revenue from Contracts with Customers (Topic 606) which requires a company to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services.   For trade sales, the Company generates its revenue from sales contracts with customers with revenues being generated upon the shipment of merchandise, or for consulting services, revenue is recognized in the period services are rendered and earned under service arrangements with clients.   We sell our products through two main sales channels: 1) directly to customers who use our products (the “Direct Channel”) and 2) to distribution partners who resell our products (the “Indirect Channel”).   Under the Direct Channel, we sell our products to and we receive payment directly from customers who purchase our products. Under our Indirect Channel, we have entered into distribution agreements that allow the distributors to sell our products and fulfill performance obligations under the agreements.   We determine revenue recognition through the following steps:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 48px">●</td> <td>Identification of the contract, or contracts, with a customer</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>●</td> <td>Identification of the performance obligations in the contract</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>●</td> <td>Determination of the transaction price</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>●</td> <td>Allocation of the transaction price to the performance obligations in the contract</td></tr> <tr style="vertical-align: top"> <td> </td> <td> </td> <td> </td></tr> <tr style="vertical-align: top"> <td> </td> <td>●</td> <td>Recognition of revenue when, or as, we satisfy a performance obligation.</td></tr> </table>   Revenue is generally recognized upon shipment or when a service has been completed, unless we have significant performance obligations for services still to be completed. We recognize revenue when a material reversal is no longer probable. Payments received before the relevant criteria for revenue recognition are satisfied are recorded as deferred revenue. There was no deferred revenue at December 31, 2020 and 2019.   Non-controlling Interests   In December 2018, PSI entered into a Joint Venture Agreement with GEN2 for further development, marketing, licensing and/or sale of PSI technology and products. Pursuant to the Joint Venture Agreement, the venture will be conducted through NEO Phototherapy, Inc. (“NEO”). PSI and GEN2 will be the members of NEO, owning 50.5% and 36.0%, respectively, of the Units issued in connection with the organization of NEO. An additional 13.5% of such Units will be reserved for issuance as incentives for key employees and consultants. As of September 30, 2019, GEN2 had received $975,000 of investments to contribute to NEO. As of April 30, 2020, the Company controlled 51% of the joint venture, GEN2 controlled 39% and another individual controlled the remaining 10%.   Effective April 30, 2020, the joint venture with GEN2 was reorganized. GEN2 shareholders exchanged their common shares in GEN2, and the individual exchanged his membership interests in NEO, for common shares representing 49% ownership in PSI. The Company retained its common shares in PSI, which provides the Company a 51% economic interest in the PSI technology and products developed by the joint venture. During three months ended December 31, 2020, PSI recorded a loss of $151,433 relating to its operations, of which $74,202 was allocated to the non-controlling interest.   Repayment of the $975,000 investment will begin through and upon the date which PSI has realized and retained cumulative net income/distributable cash in the amount of $300,000. The minority interest of PSI ownership consists of accredited investors, and investment participation of $750,000 from several WCUI officers and directors, including Calvin R. O’Harrow and Roy M. Harsch.   In May 2020, the Company’s subsidiary, PSI, agreed to become a majority shareholder in Protec Scientific, Inc. (“Protec”), a company formed in April 2020 by John Yorke for the purpose of designing, developing and marketing products that use spectral photonic emissions across a variety of applications. As of September 30, 2020, PSI had advanced $191,000 to Protec in furtherance of its agreement to acquire approximately 62% of Protec, with the Company’s share being approximately 32%, based on its PSI ownership. The remaining 30% share is to be attributed to PSI’s minority shareholders, based on their PSI ownership. During the year ended September 30, 2020, Protec received an additional $120,000 from non-affiliated investors, of which $74,400 was recorded to additional paid-in capital and $45,600 to the non-controlling interests. The additional investments gave the non-controlling interests a 38% ownership interest in Protec. During the three months ended December 31, 2020, Protec recorded a loss of $101,492, of which $69,400 was allocated to the non-controlling interests.   Inventories   Inventories are stated at the lower of cost or net realizable value. Cost is computed on a first-in, first-out basis. At December 31, 2020, primarily all of the inventories consisted of raw materials or work-in-progress. The Company provides inventory reserves based on excess and obsolete inventories determined primarily by future demand forecasts. The write down amount, if any, is measured as the difference between the cost of the inventory and net realizable value based upon assumptions about future demand and charged to the provision for inventory, which is a component of cost of sales. At the point of the loss recognition, a new, lower cost basis for that inventory is established, and subsequent changes in facts and circumstances do not result in the restoration or increase in that newly established cost basis. At December 31, 2020, the Company recorded a reserve of $50,000 for excess and slow moving inventories. At September 30, 2020, no reserve was recorded for excess, slow moving or obsolete inventory.   Stock-Based Compensation   The Company periodically issues stock-based compensation to officers, directors, and consultants for services rendered, and as part of financing transactions. Such issuances vest and expire according to terms established at the issuance date. Stock-based payments to officers, directors, employees, and for acquiring goods and services from non-employees, which include grants of employee stock options, are recognized in the financial statements based on their fair values in accordance with Topic 718. Stock option grants, which are generally time vested, will be measured at the grant date fair value and charged to operations on a straight-line basis over the vesting period.   The fair value of the Company’s common stock option and warrant grants are estimated using a Black-Scholes Merton option pricing model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the common stock options, estimated forfeitures and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes option pricing model, and based on actual experience. The assumptions used in the Black-Scholes Merton option pricing model could materially affect compensation expense recorded in future periods.   Recently Issued Accounting Pronouncements   In June 2016, the FASB issued ASU No. 2016-13, Credit Losses - Measurement of Credit Losses on Financial Instruments (“ASC 326”). The standard significantly changes how entities will measure credit losses for most financial assets, including accounts and notes receivables. The standard will replace today’s “incurred loss” approach with an “expected loss” model, under which companies will recognize allowances based on expected rather than incurred losses. Entities will apply the standard’s provisions as a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective. The standard is effective for interim and annual reporting periods beginning after December 15, 2019. The adoption of ASU 2016-13 is not expected to have a material impact on the Company’s financial position, results of operations, and cash flows.   Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

Inventories   Inventories are stated at the lower of cost or net realizable value. Cost is computed on a first-in, first-out basis. At December 31, 2020, primarily all of the inventories consisted of raw materials or work-in-progress. The Company provides inventory reserves based on excess and obsolete inventories determined primarily by future demand forecasts. The write down amount, if any, is measured as the difference between the cost of the inventory and net realizable value based upon assumptions about future demand and charged to the provision for inventory, which is a component of cost of sales. At the point of the loss recognition, a new, lower cost basis for that inventory is established, and subsequent changes in facts and circumstances do not result in the restoration or increase in that newly established cost basis. At December 31, 2020, the Company recorded a reserve of $50,000 for excess and slow moving inventories. At September 30, 2020, no reserve was recorded for excess, slow moving or obsolete inventory.

NOTE 5 – LEASE LIABILITIES   Operating Lease   In February 2019, the Company’s PSI subsidiary entered into a 24-month non-cancellable lease for its office facilities that will require monthly payments of $1,850 through January 2021. The Company adopted ASU 2016-02, Leases, effective October 1, 2019, which requires a lessee to record a right-of-use asset and a corresponding lease liability at the inception of the lease initially measured at the present value of the lease payments. The Company classified the lease as an operating lease and determined that the value of the lease asset and liability at the inception of the lease was $27,841, using a discount rate of 4.00%. As of September 30, 2020, the value of the lease asset and liability was $6,961, respectively. During the three months ended December 31, 2020, the Company made payments of $5,348 towards the lease liability. As of December 31, 2020, the lease liability amounted to $1,613.   ASU 2016-02 requires recognition in the statement of operations of a single lease cost, calculated so that the cost of the lease is allocated over the lease term, generally on a straight-line basis. Rent expense for the three months ended December 31, 2020 was $5,348. During the three months ended December 31, 2020, the Company reflected amortization of the right of use asset of $5,348 related to this lease, resulting in a net asset balance of 1,613 as of December 31, 2020.   Other Leases   The Company leased its corporate office facility in Hoffman Estates, Illinois pursuant to a non-cancellable lease initiated in July 2016 and expiring February 28, 2024. The lease terms require a monthly payment of approximately $11,000. The Company vacated the facility in April 2019, in favor of its present facilities in Tucson AZ, which are provided by a shareholder on a rent-free basis. The Company is in negotiations with the owners regarding the settlement of its lease obligations and expects that the property will be subleased or a settlement with the landlord will be reached at an amount significantly less than the remaining payment obligations. At the date of abandonment, the Company had a remaining lease obligation of $631,587.   On or about June 29, 2020, we received notice that Hanover Hoffman Estates, LLC (“HHE”), filed case number 2020L006092 in the Circuit Court of Cook County alleging our failure to pay Base Rent and abandonment of certain office space in Hoffman Estates, Illinois subject to a Commercial Lease dated May 26, 2016. HHE seeks at least $672,878 in base rent and other amounts under the lease, as well as treble damages from our ex-CEO and two past Directors who were serving on our Board as of the date of the lease. We are currently evaluating the allegations, defenses and alternate actions. As of December 31, 2020, the Company has recorded the full amount of the judgement due.

NOTE 6 – SHAREHOLDERS’ EQUITY   Restricted Stock Grants   In April 2020, the Company’s Board of Directors approved the issuance of a combined total of 20,170,000 restricted shares of the Company’s common stock to its Officers and Directors. A total of 7,120,000 shares vested in April 2020, while 1,800,000 will vest monthly from April 2020 through March 2021, and 11,250,000 will vest monthly from April 2020 through March 2023. Of the 13,050,000 shares that vest over time, a total of 1,387,500 shares vested during the three months ended December 31, 2020.   The following table summarizes restricted common stock activity:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Number of Restricted Shares</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Fair Value</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Weighted Average Grant Date Fair Value</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 49%">Non-vested, September 30, 2020</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">10,275,000</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">308,250</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">0.03</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Vested</td> <td> </td> <td> </td> <td style="text-align: right">(1,387,500</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">(41,625</td> <td>)</td> <td> </td> <td> </td> <td style="text-align: right">0.03</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Forfeited</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Non-vested, December 31, 2020</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">8,887,500</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">266,625</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.03</td> <td> </td></tr> </table>   During the three months ended December 31, 2020, the Company recorded $41,625 of stock compensation for the value of restricted common stock vesting during the period, and as of December 31, 2020, unvested compensation of $266,625 remained that will be amortized over the remaining vesting period.   Stock Options   On December 22, 2010, effective retroactively as of June 30, 2010, the Company’s Board of Directors approved the adoption of the “2010 Non-Qualified Stock Option Plan” (“2010 Option Plan”) by unanimous consent. The 2010 Option Plan was initiated to encourage and enable officers, directors, consultants, advisors and key employees of the Company to acquire and retain a proprietary interest in the Company by ownership of its common stock. A total of 7,500,000 of the authorized shares of the Company’s common stock may be subject to, or issued pursuant to, the terms of the plan. Effective January 1, 2018, the Board of Directors approved to increase the number of authorized shares of the Company’s common stock that may be subject to, or issued pursuant to, the terms of the plan from 7,500,000 to 30,000,000.   The Company’s policy is to recognize compensation cost for awards with only service conditions and a graded vesting schedule on a straight-line basis over the requisite service period for the entire award. Additionally, the Company’s policy is to issue new shares of common stock to satisfy stock option exercises. The Company applied fair value accounting for all share based payments awards. The fair value of each option granted is estimated on the date of grant using the Black-Scholes option-pricing model.   The table below summarizes the Company’s stock option activities for the three months ended December 31, 2020:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Number of Option Shares</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Exercise Price Range Per Share</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 50%">Balance, September 30, 2020</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">14,127,738</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">0.03 - 2.00</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">0.29</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Cancelled</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Exercised</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expired</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">(1,462,500</td> <td>)</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.14 - 2.00</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1.41</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Balance, December 31, 2020</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">12,665,238</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.03 - 0.40</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.10</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Vested and exercisable, December 31, 2020</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">9,702,738</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.03 - 0.40</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.12</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Unvested, December 31, 2020</td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">2,962,500</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.04</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.04</td> <td> </td></tr> </table>   The following table summarizes information concerning outstanding and exercisable options as of December 31, 2020:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center">Options Outstanding</td> <td> </td> <td> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center">Options Exercisable</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1.5pt solid">Range of Exercise Prices</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Number Outstanding</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Average Remaining Contractual Life (in years)</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Number Exercisable</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Average Remaining Contractual Life (in years)</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 1%">$</td> <td style="width: 17%; text-align: right">0.03 - 0.39</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">12,602,738</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">6.75</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">0.09</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">9,640,238</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">5.85</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">0.12</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.40</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">62,500</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1.25</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.40</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">62,500</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">1.25</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.40</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.03 - 0.40</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">12,665,238</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">6.72</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.10</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">9,702,738</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">5.82</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.12</td> <td> </td></tr> </table>   During the three months ended December 31, 2020, the Company recorded $10,882 of stock compensation for the value of options vesting during the period, and as of December 31, 2020, unvested compensation of $85,882 remained that will be amortized over the remaining vesting period.   The total aggregate intrinsic value for option shares outstanding at December 31, 2020 was $126,625. As of December 31, 2020, there were 17,334,762 shares of stock options remaining available for issuance under the 2010 Plan.   Stock Warrants   The table below summarizes the Company’s warrants activities for the three months ended December 31, 2020:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid"> Number of Warrant Shares</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Exercise Price Range Per Share</td> <td style="text-align: center"> </td> <td style="text-align: center"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="2"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 50%">Balance, September 30, 2020</td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 14%; text-align: right">67,634,049</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">0.07 - 0.40</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 13%; text-align: right">0.16</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Granted</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Cancelled</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Exercised</td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td> <td> </td> <td> </td> <td style="text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Expired</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">-</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td>Balance, December 31, 2020</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">67,634,049</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.07 - 0.40</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.16</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td>Vested and exercisable, December 31, 2020</td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">67,634,049</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.07 - 0.40</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid">$</td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.16</td> <td> </td></tr> </table>   The following table summarizes information concerning outstanding and exercisable warrants as of December 31, 2020:   <table cellspacing="0" cellpadding="0" style="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td colspan="2"> </td> <td> </td> <td> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center">Warrants Outstanding</td> <td> </td> <td> </td> <td colspan="10" style="border-bottom: black 1.5pt solid; text-align: center">Warrants Exercisable</td> <td> </td></tr> <tr style="vertical-align: bottom"> <td colspan="2" style="border-bottom: black 1.5pt solid">Range of Exercise Prices</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Number Outstanding</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Average Remaining Contractual Life (in years)</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Number Exercisable</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Average Remaining Contractual Life (in years)</td> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center">Weighted Average Exercise Price</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 1%">$</td> <td style="width: 17%; text-align: right">0.12 – 0.20</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">60,429,384</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right">1.74</td> <td style="width: 1%"> </td> <td style="width: 2%"> </td> <td style="width: 1%">$</td> <td style="width: 11%; text-align: right">0.15</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">60,429,384</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 9%; text-align: right">1.74</td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%">$</td> <td style="width: 9%; text-align: right">0.15</td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"> 0.21 – 0.40</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">7,204,665</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.64</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.26</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">7,204,665</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.64</td> <td> </td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right">0.26</td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.12 – 0.67</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">67,634,049</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1.62</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.16</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">67,634,049</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double"> </td> <td style="border-bottom: black 2.25pt double; text-align: right">1.62</td> <td> </td> <td> </td> <td style="border-bottom: black 2.25pt double">$</td> <td style="border-bottom: black 2.25pt double; text-align: right">0.16</td> <td> </td></tr> </table>   There was no aggregate intrinsic value for warrant shares outstanding at December 31, 2020.

NOTE 9 – SUBSEQUENT EVENTS   Subsequent to December 31, 2020, the Company borrowed $355,000 from its officers and shareholders. All of the loans are unsecured, have an interest rate of eight percent and are due one year from the date of issuance.   On April 1, 2021, the Company’s Board of Directors approved the issuance of a combined total of 3,750,000 restricted shares of the Company’s common stock to certain of its Officers and Directors for future services to be performed. The shares vest monthly from April 2023 through March 2024. The fair value of the shares on the date of grant was $187,500.   The Board also approved the issuance of a combined total of 10,085,714 restricted shares of the Company’s common stock to certain of its Officers and Directors in connection with their officer and shareholder loans. A total of 7,060,000 of the shares vested upon grant and 3,025,714 shares vest in April 2025. The fair value of the shares on the date of grant was $504,286.   On April 1, 2021, the Company’s Board of Directors approved the grant of stock options to its Chief Executive Officer (CEO) to purchase 1,300,000 shares of the Company’s common stock with an exercise price of $0.05 per share. The options expire ten years from the date of grant. The option grants are for future services to be performed by the CEO. The shares vest monthly from April 2023 through March 2024. The fair value of the shares on the date of grant was approximately $65,000.   The Board also approved the grant of stock options to its CEO to purchase 13,449,429 shares of the Company’s common stock with an exercise price of $0.05 per share. The options expire ten years from the date of grant. The option grants are in connection with his officer and shareholder loans. A total of 9,052,500 of the shares vested upon grant and 4,396,929 shares vest in April 2025. The fair value of the shares on the date of grant was approximately $670,000. In connection with the option grants, the CEO agreed to cancel 5,277,778 of his warrant shares that were scheduled to expire from September 2021 through December 2021.

Effective April 30, 2020, the Company's 51% interest in NEO was converted into a 51% interest in PSI.

EX-101.SCH 7 wcui-20201231.xsd XBRL SCHEMA FILE 00000001 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Shareholders' Deficit (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - Loans Payable from Officers and Shareholders link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - U.S. Small Business Administration Loan Payable link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - Lease Liabilities link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - Segment Reporting link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - Legal Matters link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - Shareholders' Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - Segment Reporting (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - Basis of Presentation (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - Summary of Significant Accounting Policies - Schedule of Company's Consolidated Subsidiaries (Details) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - Summary of Significant Accounting Policies - Schedule of Company's Consolidated Subsidiaries (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - Loans Payable from Officers and Shareholders (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - U.S. Small Business Administration Loan Payable (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - Lease Liabilities (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - Shareholders' Equity (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - Shareholders' Equity - Summary of Restricted Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - Shareholders' Equity - Schedule of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - Shareholders' Equity - Schedule of Outstanding and Exercisable Options by Exercise Price Range (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - Shareholders' Equity - Schedule of Warrant Activity (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - Shareholders' Equity - Schedule of Outstanding and Exercisable Warrants by Exercise Price Range (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - Segment Reporting - Schedule of Assets of Reportable Segments (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - Segment Reporting - Schedule of Operations of Reportable Segments (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - Legal Matters (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - Subsequent Events (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 wcui-20201231_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 wcui-20201231_def.xml XBRL DEFINITION FILE EX-101.LAB 10 wcui-20201231_lab.xml XBRL LABEL FILE Plan Name [Axis] 2010 Non-Qualified Stock Option Plan [Member] Segments [Axis] Corporate [Member] Medical Devices [Member] Authentication and Encryption [Member] Title of Individual [Axis] Employees and Consultants [Member] Legal Entity [Axis] GEN2 [Member] Individual [Member] Board of Directors [Member] Vesting [Axis] Vest Monthly from April 2020 Through March 2021 [Member] Vest Monthly from April 2020 Through March 2023 [Member] Vest Over Time [Member] Ownership [Axis] Protec Scientific, Inc [Member] Hanover Hoffman Estates LLC [Member] Ex- Employee [Member] Range [Axis] Minimum [Member] Maximum [Member] Exercise Price Range [Axis] Exercise Price Range One [Member] Exercise Price Range Two [Member] Equity Components [Axis] Warrant [Member] Antidilutive Securities [Axis] Stock Option [Member] Warrants [Member] Psoria-Shield, Inc [Member] StealthCo, Inc. [Member] Psoria Development Company LLC. [Member] NEO Phototherapy, LLC, [Member] Award Date [Axis] April 30, 2020 [Member] Former CEO [Member] Award Type [Axis] Restricted Stock [Member] Stock Option [Member] 2010 Non-Qualified Stock Option Plan [Member] Subsequent Event Type [Axis] Subsequent Event [Member] April 2023 Through March 2024 [Member] Officers and Directors [Member] April 2025 [Member] CEO [Member] September 2021 through December 2021 [Member] Common Stock [Member] Additional Paid-in Capital [Member] Accumulated Deficit [Member] Total WCUI Deficit [Member] Non-controlling Interest [Member] Gen 2 Funding, Inc [Member] Non-affiliated Investors [Member] Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Document Period End Date Amendment Flag Current Fiscal Year End Date Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Flag Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Document Fiscal Period Focus Document Fiscal Year Focus Statement of Financial Position [Abstract] ASSETS Current Assets Cash Accounts receivable Inventories Prepaid expenses and other current assets Total Current Assets Right of use asset Total Other Assets TOTAL ASSETS LIABILITIES AND SHAREHOLDERS' DEFICIT Current Liabilities Accounts payable and accrued expenses Payroll taxes payable - past due Lease liability Lease abandonment liability Loans payable from officers and shareholders, including $504,250 past due at December 31, 2020 Total Current Liabilities Long-term Liabilities U.S. Small Business Administration PPP loan payable Total Liabilities Shareholders' Deficit Common stock, par value $0.001, 200,000,000 shares authorized; 119,639,577 and 118,252,077 shares issued and outstanding, respectively Additional paid-in capital Accumulated deficit Total Wellness Center USA shareholders' deficit Non-controlling interest Total Shareholder's deficit TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT Loans payable from officers and shareholders, past due amount Common stock, par value Common stock, shares authorized Common stock, shares, issued Common stock, shares, outstanding Income Statement [Abstract] Trade sales Cost of goods sold Gross profit Operating expenses Loss from operations Other expense Interest expense Total other expense NET LOSS Net loss attributable to non-controlling interest NET LOSS ATTRIBUTABLE TO WELLNESS CENTER USA, INC. BASIC AND DILUTED LOSS PER SHARE WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING BASIC AND DILUTED Statement [Table] Statement [Line Items] Balance Balance, shares Fair value of vested stock options Contribution of capital by joint venture partners Fair value of common stock issued for services Fair value of common stock issued for services, shares Net loss Balance Balance, shares Statement of Cash Flows [Abstract] Cash Flows from Operating Activities Adjustments to reconcile net loss to net cash used in operating activities: Depreciation expense Amortization of right-of-use asset Provision for excess and slow moving inventories Fair value of common shares issued for services Fair value of stock options issued for services Changes in Assets and Liabilities (Increase) Decrease in: Accounts receivable Inventories Prepaid expenses and other assets (Decrease) Increase in: Accounts payable and accrued expenses Payroll taxes payable Lease liability Net cash used in operating activities Cash Flows from Financing Activities Proceeds from loans payable from officers and shareholders Contribution of capital by joint venture partner Net cash provided by financing activities Net increase (decrease) in cash Cash beginning of period Cash end of period Supplemental cash flows disclosures: Interest paid Taxes paid Supplemental non-cash disclosures: Initial recognition of right-of-use assets and operating lease liabilities upon adoption of ASC Topic 842 Accounting Policies [Abstract] Basis of Presentation Summary of Significant Accounting Policies Debt Disclosure [Abstract] Loans Payable from Officers and Shareholders U.s. Small Business Administration Loan Payable U.S. Small Business Administration Loan Payable Leases [Abstract] Lease Liabilities Equity [Abstract] Shareholders' Equity Segment Reporting [Abstract] Segment Reporting Commitments and Contingencies Disclosure [Abstract] Legal Matters Subsequent Events [Abstract] Subsequent Events Basis of Consolidation Use of Estimates Income (Loss) Per Share Revenue Recognition Non-controlling Interests Inventories Stock-based Compensation Recently Issued Accounting Pronouncements Schedule of Company's Consolidated Subsidiaries Summary of Restricted Common Stock Schedule of Stock Option Activity Schedule of Outstanding and Exercisable Options by Exercise Price Range Schedule of Warrant Activity Schedule of Outstanding and Exercisable Warrants by Exercise Price Range EX-101.PRE 11 wcui-20201231_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT

Document and Entity Information	3 Months Ended
Document and Entity Information	Dec. 31, 2020 shares
Cover [Abstract]
Entity Registrant Name	Wellness Center USA, Inc.
Entity Central Index Key	0001516887
Document Type	10-Q
Document Period End Date	Dec. 31, 2020
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding	119,639,577
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2021

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($)	Dec. 31, 2020	Sep. 30, 2020
Current Assets
Cash	$ 78,523	$ 51,320
Accounts receivable	23,989
Inventories	134,522	94,560
Prepaid expenses and other current assets	500	500
Total Current Assets	237,534	146,380
Right of use asset	1,613	6,961
Total Other Assets	1,613	6,961
TOTAL ASSETS	239,147	153,341
Current Liabilities
Accounts payable and accrued expenses	480,744	408,297
Payroll taxes payable - past due	87,834	92,334
Lease liability	1,613	6,961
Lease abandonment liability	672,878	672,878
Loans payable from officers and shareholders, including $504,250 past due at December 31, 2020	1,460,250	1,165,250
Total Current Liabilities	2,703,319	2,345,720
Long-term Liabilities
U.S. Small Business Administration PPP loan payable	37,166	37,166
Total Liabilities	2,740,485	2,382,886
Shareholders' Deficit
Common stock, par value $0.001, 200,000,000 shares authorized; 119,639,577 and 118,252,077 shares issued and outstanding, respectively	119,639	118,252
Additional paid-in capital	25,104,736	25,053,616
Accumulated deficit	(27,764,061)	(27,583,363)
Total Wellness Center USA shareholders' deficit	(2,539,686)	(2,411,495)
Non-controlling interest	38,348	181,950
Total Shareholder's deficit	(2,501,338)	(2,229,545)
TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT	$ 239,147	$ 153,341

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2020	Sep. 30, 2020
Statement of Financial Position [Abstract]
Loans payable from officers and shareholders, past due amount	$ 504,250
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares, issued	119,639,577	118,252,077
Common stock, shares, outstanding	119,639,577	118,252,077

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Trade sales	$ 90,499
Cost of goods sold	80,100
Gross profit	10,399
Operating expenses	308,541	337,273
Loss from operations	(298,142)	(337,273)
Other expense
Interest expense	(26,158)	(9,323)
Total other expense	(26,158)	(9,323)
NET LOSS	(324,300)	(346,596)
Net loss attributable to non-controlling interest	143,602	22,129
NET LOSS ATTRIBUTABLE TO WELLNESS CENTER USA, INC.	$ (180,698)	$ (324,467)
BASIC AND DILUTED LOSS PER SHARE	$ (0.00)	$ (0.00)
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING BASIC AND DILUTED	118,960,909	107,497,077

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Shareholders' Deficit (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total WCUI Deficit [Member]	Non-controlling Interest [Member]	Total
Balance at Sep. 30, 2019	$ 107,497	$ 23,777,647	$ (25,362,287)	$ (1,477,143)	$ 393,149	$ (2,229,545)
Balance, shares at Sep. 30, 2019	107,497,077
Fair value of vested stock options		65,738		65,738		65,738
Contribution of capital by joint venture partners		25,500		25,500	24,500	50,000
Net loss			(324,467)	(324,467)	(22,129)	(346,596)
Balance at Dec. 31, 2019	$ 107,497	23,868,885	(25,686,754)	(1,710,372)	395,520	(1,314,852)
Balance, shares at Dec. 31, 2019	107,497,077
Balance at Sep. 30, 2020	$ 118,252	25,053,616	(27,583,363)	(2,411,495)	181,950	(2,229,545)
Balance, shares at Sep. 30, 2020	118,252,077
Fair value of vested stock options		10,882		10,882		10,882
Fair value of common stock issued for services	$ 1,387	40,238		41,625		41,625
Fair value of common stock issued for services, shares	1,387,500
Net loss			(180,698)	(180,698)	(143,602)	(324,300)
Balance at Dec. 31, 2020	$ 119,639	$ 25,104,736	$ (27,764,061)	$ (2,539,686)	$ 38,348	$ (2,501,338)
Balance, shares at Dec. 31, 2020	119,639,577

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (a)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 235
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-URI http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1A
-Subparagraph (c)(1)
-URI http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684

Reference 14: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 20: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4K
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

- Definition

Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 24
-URI http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 23
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 326
-SubTopic 10
-Section 65
-Paragraph 4
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (f)(2)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4I
-URI http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 40
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-URI http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 45
-Paragraph 20
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 45
-Paragraph 5
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793

Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (f)(1)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(3)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 830
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 65
-Paragraph 15
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (d)(2)

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 65
-Paragraph 8
-Subparagraph (d)(3)

+ Details

XML 17 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Cash Flows from Operating Activities
Net loss	$ (324,300)	$ (346,596)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense		1,562
Amortization of right-of-use asset	5,348	5,144
Provision for excess and slow moving inventories	50,000
Fair value of common shares issued for services	41,625
Fair value of stock options issued for services	10,882	65,738
(Increase) Decrease in:
Accounts receivable	(23,989)
Inventories	(89,962)
Prepaid expenses and other assets		(500)
(Decrease) Increase in:
Accounts payable and accrued expenses	72,447	84,012
Payroll taxes payable	(4,500)
Lease liability	(5,348)	(5,144)
Net cash used in operating activities	(267,797)	(195,784)
Cash Flows from Financing Activities
Proceeds from loans payable from officers and shareholders	295,000	135,000
Contribution of capital by joint venture partner		50,000
Net cash provided by financing activities	295,000	185,000
Net increase (decrease) in cash	27,203	(10,784)
Cash beginning of period	51,320	53,147
Cash end of period	78,523	42,363
Supplemental cash flows disclosures:
Interest paid
Taxes paid
Supplemental non-cash disclosures:
Initial recognition of right-of-use assets and operating lease liabilities upon adoption of ASC Topic 842		$ 27,841

XML 18 R7.htm IDEA: XBRL DOCUMENT

Basis of Presentation

3 Months Ended

Dec. 31, 2020

Accounting Policies [Abstract]

Basis of Presentation

NOTE 1 – BASIS OF PRESENTATION

Organization and Operations

Basis of Presentation of Unaudited Financial Information

COVID-19 Considerations

Going Concern

XML 19 R8.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

3 Months Ended

Dec. 31, 2020

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Consolidation

Name of consolidated subsidiary or entity	State or other jurisdiction of incorporation or organization	Date of incorporation or formation (date of acquisition/disposition, if applicable)	Attributable interest at September 30, 2019			Attributable interest at September 30, 2020
Psoria-Shield Inc. (“PSI”)	The State of Florida	June 2009 (August 2012)		100	%		51	%(1)
StealthCo, Inc. (“StealthCo”)	The State of Illinois	March 2014		100	%		100	%
Psoria Development Company LLC. (“PDC”)	The State of Illinois	January 2015/ November 2018		0	%		0	%
NEO Phototherapy LLC (“NEO”)	The State of Illinois	December 2018		51	%(1)		0	%
Protec Scientific, Inc (“Protec”)	The State of New York	April 2020		0	%		38	%

(1) - Effective April 30, 2020, the Company’s 51% interest in NEO was converted into a 51% interest in PSI.

Use of Estimates

Income (Loss) Per Share

Revenue Recognition

We determine revenue recognition through the following steps:

	●	Identification of the contract, or contracts, with a customer

	●	Identification of the performance obligations in the contract

	●	Determination of the transaction price

	●	Allocation of the transaction price to the performance obligations in the contract

	●	Recognition of revenue when, or as, we satisfy a performance obligation.

Non-controlling Interests

Inventories

Stock-Based Compensation

Recently Issued Accounting Pronouncements

XML 20 R9.htm IDEA: XBRL DOCUMENT

Loans Payable from Officers and Shareholders

3 Months Ended

Dec. 31, 2020

Debt Disclosure [Abstract]

Loans Payable from Officers and Shareholders

NOTE 3 – LOANS PAYABLE FROM OFFICERS AND SHAREHOLDERS

XML 21 R10.htm IDEA: XBRL DOCUMENT

U.S. Small Business Administration Loan Payable

3 Months Ended

Dec. 31, 2020

U.s. Small Business Administration Loan Payable

U.S. Small Business Administration Loan Payable

NOTE 4 – U.S. SMALL BUSINESS ADMINISTRATION LOAN PAYABLE

XML 22 R11.htm IDEA: XBRL DOCUMENT

Lease Liabilities

3 Months Ended

Dec. 31, 2020

Leases [Abstract]

Lease Liabilities

NOTE 5 – LEASE LIABILITIES

Operating Lease

Other Leases

XML 23 R12.htm IDEA: XBRL DOCUMENT

Shareholders' Equity

3 Months Ended

Dec. 31, 2020

Equity [Abstract]

Shareholders' Equity

NOTE 6 – SHAREHOLDERS’ EQUITY

Restricted Stock Grants

The following table summarizes restricted common stock activity:

	Number of Restricted Shares			Fair Value			Weighted Average Grant Date Fair Value

Non-vested, September 30, 2020		10,275,000		$	308,250		$	0.03
Granted		-			-			-
Vested		(1,387,500	)		(41,625	)		0.03
Forfeited		-			-			-
Non-vested, December 31, 2020		8,887,500		$	266,625		$	0.03

Stock Options

The table below summarizes the Company’s stock option activities for the three months ended December 31, 2020:

	Number of Option Shares			Exercise Price Range Per Share		Weighted Average Exercise Price

Balance, September 30, 2020		14,127,738		$	0.03 - 2.00	$	0.29
Granted		-			-		-
Cancelled		-			-		-
Exercised		-			-		-
Expired		(1,462,500	)		0.14 - 2.00		1.41
Balance, December 31, 2020		12,665,238		$	0.03 - 0.40	$	0.10
Vested and exercisable, December 31, 2020		9,702,738		$	0.03 - 0.40	$	0.12

Unvested, December 31, 2020		2,962,500		$	0.04	$	0.04

The following table summarizes information concerning outstanding and exercisable options as of December 31, 2020:

		Options Outstanding						Options Exercisable
Range of Exercise Prices		Number Outstanding		Average Remaining Contractual Life (in years)		Weighted Average Exercise Price		Number Exercisable		Average Remaining Contractual Life (in years)		Weighted Average Exercise Price

$	0.03 - 0.39		12,602,738		6.75	$	0.09		9,640,238		5.85	$	0.12
	0.40		62,500		1.25		0.40		62,500		1.25		0.40
$	0.03 - 0.40		12,665,238		6.72	$	0.10		9,702,738		5.82	$	0.12

Stock Warrants

The table below summarizes the Company’s warrants activities for the three months ended December 31, 2020:

	Number of Warrant Shares		Exercise Price Range Per Share		Weighted Average Exercise Price

Balance, September 30, 2020		67,634,049	$	0.07 - 0.40	$	0.16
Granted		-		-		-
Cancelled		-		-		-
Exercised		-		-		-
Expired		-		-		-
Balance, December 31, 2020		67,634,049	$	0.07 - 0.40	$	0.16
Vested and exercisable, December 31, 2020		67,634,049	$	0.07 - 0.40	$	0.16

The following table summarizes information concerning outstanding and exercisable warrants as of December 31, 2020:

		Warrants Outstanding						Warrants Exercisable
Range of Exercise Prices		Number Outstanding		Average Remaining Contractual Life (in years)		Weighted Average Exercise Price		Number Exercisable		Average Remaining Contractual Life (in years)		Weighted Average Exercise Price

$	0.12 – 0.20		60,429,384		1.74	$	0.15		60,429,384		1.74	$	0.15
	0.21 – 0.40		7,204,665		0.64		0.26		7,204,665		0.64		0.26

$	0.12 – 0.67		67,634,049		1.62	$	0.16		67,634,049		1.62	$	0.16

There was no aggregate intrinsic value for warrant shares outstanding at December 31, 2020.

XML 24 R13.htm IDEA: XBRL DOCUMENT

Segment Reporting

3 Months Ended

Dec. 31, 2020

Segment Reporting [Abstract]

Segment Reporting

NOTE 7 – SEGMENT REPORTING

The Company operates in the following business segments:

The detailed segment information of the Company is as follows:

Assets By Segment

	December 31, 2020
	Corporate		Medical Devices		Authentication and Encryption		Total
ASSETS
Current Assets
Cash	$	8,178	$	67,709	$	2,636	$	78,523
Accounts receivable		-		23,989		-		23,989
Inventories		-		134,522		-		134,522
Prepaid expenses and other current assets		500		-		-		500
Total current assets		8,678		226,220		2,636		237,534

Right of use asset		-		1,613		-		1,613
Total other assets		-		1,613		-		1,613

TOTAL ASSETS	$	8,678	$	227,833	$	2,636	$	239,147

Operations by Segment

	For the Three Months Ended
	December 31, 2020
	Corporate			Medical Devices			Authentication and Encryption			Total

Trade sales	$	-		$	90,499		$	-		$	90,499

Cost of goods sold		-			80,100			-			80,100

Gross profit		-			10,399			-			10,399

Operating expenses		49,109			256,471			2,961			308,541

Loss from operations	$	(49,109	)	$	(246,072	)	$	(2,961	)	$	(298,142	)

	For the Three Months Ended
	December 31, 2019
	Corporate			Medical Devices			Authentication and Encryption			Total

Trade sales	$	-		$	-		$	-		$	-

Cost of goods sold		-			-			-			-

Gross profit		-			-			-			-

Operating expenses		98,462			175,286			63,525			337,273

Loss from operations	$	(98,462	)	$	(175,286	)	$	(63,525	)	$	(337,273	)

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 21
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-URI http://asc.fasb.org/topic&trid=2134510

+ Details

XML 25 R14.htm IDEA: XBRL DOCUMENT

Legal Matters

3 Months Ended

Dec. 31, 2020

Commitments and Contingencies Disclosure [Abstract]

Legal Matters

NOTE 8 – LEGAL MATTERS

XML 26 R15.htm IDEA: XBRL DOCUMENT

Subsequent Events

3 Months Ended

Dec. 31, 2020

Subsequent Events [Abstract]

Subsequent Events

NOTE 9 – SUBSEQUENT EVENTS

XML 27 R16.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

3 Months Ended

Dec. 31, 2020

Accounting Policies [Abstract]

Basis of Consolidation

Basis of Consolidation

Name of consolidated subsidiary or entity	State or other jurisdiction of incorporation or organization	Date of incorporation or formation (date of acquisition/disposition, if applicable)	Attributable interest at September 30, 2019			Attributable interest at September 30, 2020
Psoria-Shield Inc. (“PSI”)	The State of Florida	June 2009 (August 2012)		100	%		51	%(1)
StealthCo, Inc. (“StealthCo”)	The State of Illinois	March 2014		100	%		100	%
Psoria Development Company LLC. (“PDC”)	The State of Illinois	January 2015/ November 2018		0	%		0	%
NEO Phototherapy LLC (“NEO”)	The State of Illinois	December 2018		51	%(1)		0	%
Protec Scientific, Inc (“Protec”)	The State of New York	April 2020		0	%		38	%

(1) - Effective April 30, 2020, the Company’s 51% interest in NEO was converted into a 51% interest in PSI.

Use of Estimates

Use of Estimates

Income (Loss) Per Share

Income (Loss) Per Share

Revenue Recognition

Revenue Recognition

We determine revenue recognition through the following steps:

	●	Identification of the contract, or contracts, with a customer

	●	Identification of the performance obligations in the contract

	●	Determination of the transaction price

	●	Allocation of the transaction price to the performance obligations in the contract

	●	Recognition of revenue when, or as, we satisfy a performance obligation.

Non-controlling Interests

Non-controlling Interests

Inventories

Inventories

Stock-based Compensation

Stock-Based Compensation

Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements

- Definition

Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.

+ References + Details

- Definition

Disclosure of accounting policy for revenue from contract with customer.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130561-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 18
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130563-203045

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 19
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130564-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 20
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130566-203045

+ Details

XML 28 R17.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

3 Months Ended

Dec. 31, 2020

Accounting Policies [Abstract]

Schedule of Company's Consolidated Subsidiaries

The Company’s consolidated subsidiaries and/or controlled entities are as follows:

Name of consolidated subsidiary or entity	State or other jurisdiction of incorporation or organization	Date of incorporation or formation (date of acquisition/disposition, if applicable)	Attributable interest at September 30, 2019			Attributable interest at September 30, 2020
Psoria-Shield Inc. (“PSI”)	The State of Florida	June 2009 (August 2012)		100	%		51	%(1)
StealthCo, Inc. (“StealthCo”)	The State of Illinois	March 2014		100	%		100	%
Psoria Development Company LLC. (“PDC”)	The State of Illinois	January 2015/ November 2018		0	%		0	%
NEO Phototherapy LLC (“NEO”)	The State of Illinois	December 2018		51	%(1)		0	%
Protec Scientific, Inc (“Protec”)	The State of New York	April 2020		0	%		38	%

(1) - Effective April 30, 2020, the Company’s 51% interest in NEO was converted into a 51% interest in PSI.

XML 29 R18.htm IDEA: XBRL DOCUMENT

Shareholders' Equity (Tables)

3 Months Ended

Dec. 31, 2020

Equity [Abstract]

Summary of Restricted Common Stock

The following table summarizes restricted common stock activity:

	Number of Restricted Shares			Fair Value			Weighted Average Grant Date Fair Value

Non-vested, September 30, 2020		10,275,000		$	308,250		$	0.03
Granted		-			-			-
Vested		(1,387,500	)		(41,625	)		0.03
Forfeited		-			-			-
Non-vested, December 31, 2020		8,887,500		$	266,625		$	0.03

Schedule of Stock Option Activity

The table below summarizes the Company’s stock option activities for the three months ended December 31, 2020:

	Number of Option Shares			Exercise Price Range Per Share		Weighted Average Exercise Price

Balance, September 30, 2020		14,127,738		$	0.03 - 2.00	$	0.29
Granted		-			-		-
Cancelled		-			-		-
Exercised		-			-		-
Expired		(1,462,500	)		0.14 - 2.00		1.41
Balance, December 31, 2020		12,665,238		$	0.03 - 0.40	$	0.10
Vested and exercisable, December 31, 2020		9,702,738		$	0.03 - 0.40	$	0.12

Unvested, December 31, 2020		2,962,500		$	0.04	$	0.04

Schedule of Outstanding and Exercisable Options by Exercise Price Range

The following table summarizes information concerning outstanding and exercisable options as of December 31, 2020:

		Options Outstanding						Options Exercisable
Range of Exercise Prices		Number Outstanding		Average Remaining Contractual Life (in years)		Weighted Average Exercise Price		Number Exercisable		Average Remaining Contractual Life (in years)		Weighted Average Exercise Price

$	0.03 - 0.39		12,602,738		6.75	$	0.09		9,640,238		5.85	$	0.12
	0.40		62,500		1.25		0.40		62,500		1.25		0.40
$	0.03 - 0.40		12,665,238		6.72	$	0.10		9,702,738		5.82	$	0.12

Schedule of Warrant Activity

The table below summarizes the Company’s warrants activities for the three months ended December 31, 2020:

	Number of Warrant Shares		Exercise Price Range Per Share		Weighted Average Exercise Price

Balance, September 30, 2020		67,634,049	$	0.07 - 0.40	$	0.16
Granted		-		-		-
Cancelled		-		-		-
Exercised		-		-		-
Expired		-		-		-
Balance, December 31, 2020		67,634,049	$	0.07 - 0.40	$	0.16
Vested and exercisable, December 31, 2020		67,634,049	$	0.07 - 0.40	$	0.16

Schedule of Outstanding and Exercisable Warrants by Exercise Price Range

The following table summarizes information concerning outstanding and exercisable warrants as of December 31, 2020:

		Warrants Outstanding						Warrants Exercisable
Range of Exercise Prices		Number Outstanding		Average Remaining Contractual Life (in years)		Weighted Average Exercise Price		Number Exercisable		Average Remaining Contractual Life (in years)		Weighted Average Exercise Price

$	0.12 – 0.20		60,429,384		1.74	$	0.15		60,429,384		1.74	$	0.15
	0.21 – 0.40		7,204,665		0.64		0.26		7,204,665		0.64		0.26

$	0.12 – 0.67		67,634,049		1.62	$	0.16		67,634,049		1.62	$	0.16

XML 30 R19.htm IDEA: XBRL DOCUMENT

Segment Reporting (Tables)

3 Months Ended

Dec. 31, 2020

Segment Reporting [Abstract]

Schedule of Assets of Reportable Segments

The detailed segment information of the Company is as follows:

Assets By Segment

	December 31, 2020
	Corporate		Medical Devices		Authentication and Encryption		Total
ASSETS
Current Assets
Cash	$	8,178	$	67,709	$	2,636	$	78,523
Accounts receivable		-		23,989		-		23,989
Inventories		-		134,522		-		134,522
Prepaid expenses and other current assets		500		-		-		500
Total current assets		8,678		226,220		2,636		237,534

Right of use asset		-		1,613		-		1,613
Total other assets		-		1,613		-		1,613

TOTAL ASSETS	$	8,678	$	227,833	$	2,636	$	239,147

Schedule of Operations of Reportable Segments

Operations by Segment

	For the Three Months Ended
	December 31, 2020
	Corporate			Medical Devices			Authentication and Encryption			Total

Trade sales	$	-		$	90,499		$	-		$	90,499

Cost of goods sold		-			80,100			-			80,100

Gross profit		-			10,399			-			10,399

Operating expenses		49,109			256,471			2,961			308,541

Loss from operations	$	(49,109	)	$	(246,072	)	$	(2,961	)	$	(298,142	)

	For the Three Months Ended
	December 31, 2019
	Corporate			Medical Devices			Authentication and Encryption			Total

Trade sales	$	-		$	-		$	-		$	-

Cost of goods sold		-			-			-			-

Gross profit		-			-			-			-

Operating expenses		98,462			175,286			63,525			337,273

Loss from operations	$	(98,462	)	$	(175,286	)	$	(63,525	)	$	(337,273	)

XML 31 R20.htm IDEA: XBRL DOCUMENT

Basis of Presentation (Details Narrative) - USD ($)	3 Months Ended
Basis of Presentation (Details Narrative) - USD ($)	Dec. 31, 2020	Dec. 31, 2019	Sep. 30, 2020	Sep. 30, 2019
Accounting Policies [Abstract]
Entity incorporation, state country name	Nevada
Net loss	$ (324,300)	$ (346,596)
Cash used in operations	(267,797)	(195,784)
Shareholders' deficit	(2,501,338)	(1,314,852)	$ (2,229,545)	$ (2,229,545)
Loans payable	504,250
Payroll taxes due	87,834		92,334
Cash on hand	78,523		$ 51,320
Short-term loans from officers	$ 295,000	$ 135,000

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

XML 32 R21.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	1 Months Ended		3 Months Ended
	May 31, 2020	Dec. 31, 2018	Dec. 31, 2020	Dec. 31, 2019	Sep. 30, 2020	Apr. 30, 2020	Sep. 30, 2019
Deferred revenue
Non-controlling interest, description		Pursuant to the Joint Venture Agreement, the venture will be conducted through NEO Phototherapy, Inc. ("NEO"). PSI and GEN2 will be the members of NEO, owning 50.5% and 36.0%, respectively, of the Units issued in connection with the organization of NEO. An additional 13.5% of such Units will be reserved for issuance as incentives for key employees and consultants. As of September 30, 2019, GEN2 had received $975,000 of investments to contribute to NEO. As of April 30, 2020, the Company controlled 51% of the joint venture, GEN2 controlled 39% and another individual controlled the remaining 10%.
Operating loss			(298,142)	$ (337,273)
Non-controlling interest			38,348		$ 181,950
Additional paid-in capital			25,104,736		25,053,616
Inventory reserves			$ 50,000
April 30, 2020 [Member]
Non-controlling interest, description			The joint venture with GEN2 was reorganized. GEN2 shareholders exchanged their common shares in GEN2, and the individual exchanged his membership interests in NEO, for common shares representing 49% ownership in PSI. The Company retained its common shares in PSI, which provides the Company a 51% economic interest in the PSI technology and products developed by the joint venture. During three months ended December 31, 2020, PSI recorded a loss of $151,433 relating to its operations, of which $74,202 was allocated to the non-controlling interest.
Operating loss			$ 151,433
Non-controlling interest			74,202
Repayment from investment			975,000
Distributable cash			300,000
GEN2 [Member]
Investments to others							$ 975,000
Employees and Consultants [Member]
Additional units reserved for issuance		13.50%
Individual [Member]
Ownership percentage						49.00%
Joint venture percentage						51.00%
Psoria-Shield, Inc [Member]
Ownership percentage		50.50%
Proceeds from investment			750,000
Additional paid-in capital					191,000
Gen 2 Funding, Inc [Member]
Ownership percentage		36.00%
Protec Scientific, Inc [Member]
Operating loss			101,492
Non-controlling interest					45,600
Additional paid-in capital					74,400
Acquisition description	In May 2020, the Company's subsidiary, PSI, agreed to become a majority shareholder in Protec Scientific, Inc. ("Protec"), a company formed in April 2020 by John Yorke for the purpose of designing, developing and marketing products that use spectral photonic emissions across a variety of applications. As of September 30, 2020, PSI had advanced $191,000 to Protec in furtherance of its agreement to acquire approximately 62% of Protec, with the Company's share being approximately 32%, based on its PSI ownership. The remaining 30% share is to be attributed to PSI's minority shareholders, based on their PSI ownership. During the year ended September 30, 2020, Protec received an additional $120,000 from non-affiliated investors, of which $74,400 was recorded to additional paid-in capital and $45,600 to the non-controlling interests. The additional investments gave the non-controlling interests a 38% ownership interest in Protec.
Loss allocated to the non-controlling interests			$ 69,400
Protec Scientific, Inc [Member] \| Non-affiliated Investors [Member]
Additional paid-in capital					$ 120,000
Stock Option [Member]
Antidilutive securities excluded from computation of earnings per share			12,665,238	15,037,738
Warrants [Member]
Antidilutive securities excluded from computation of earnings per share			67,634,049	66,484,049

XML 33 R22.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Schedule of Company's Consolidated Subsidiaries (Details)

3 Months Ended

Dec. 31, 2020

Sep. 30, 2020

Sep. 30, 2019

State or other jurisdiction of incorporation or organization

Nevada

Psoria-Shield, Inc [Member]

Name of consolidated subsidiary or entity

Psoria-Shield Inc. ("PSI")

State or other jurisdiction of incorporation or organization

The State of Florida

Month and Year of incorporation or formation

2009-06

Month and Year of acquisition/disposition

2012-08

Attributable interest

51.00%

^[1]

100.00%

StealthCo, Inc. [Member]

Name of consolidated subsidiary or entity

StealthCo, Inc. ("StealthCo")

State or other jurisdiction of incorporation or organization

The State of Illinois

Month and Year of incorporation or formation

2014-03

Attributable interest

100.00%

Psoria Development Company LLC. [Member]

Name of consolidated subsidiary or entity

Psoria Development Company LLC. ("PDC")

State or other jurisdiction of incorporation or organization

The State of Illinois

Month and Year of incorporation or formation

2015-01

Month and Year of acquisition/disposition

2018-11

Attributable interest

0.00%

NEO Phototherapy, LLC, [Member]

Name of consolidated subsidiary or entity

NEO Phototherapy LLC ("NEO")

State or other jurisdiction of incorporation or organization

The State of Illinois

Month and Year of incorporation or formation

2018-12

Attributable interest

0.00%

51.00%

^[1]

Protec Scientific, Inc [Member]

Name of consolidated subsidiary or entity

Protec Scientific, Inc ("Protec")

State or other jurisdiction of incorporation or organization

The State of New York

Month and Year of incorporation or formation

2020-04

Attributable interest

38.00%

0.00%

[1]	Effective April 30, 2020, the Company's 51% interest in NEO was converted into a 51% interest in PSI.

XML 34 R23.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies - Schedule of Company's Consolidated Subsidiaries (Details) (Parenthetical)

Sep. 30, 2020

Sep. 30, 2019

Psoria-Shield, Inc [Member]

Attributable interest

51.00%

^[1]

100.00%

NEO Phototherapy, LLC, [Member]

Attributable interest

0.00%

51.00%

^[1]

[1]	Effective April 30, 2020, the Company's 51% interest in NEO was converted into a 51% interest in PSI.

XML 35 R24.htm IDEA: XBRL DOCUMENT

Loans Payable from Officers and Shareholders (Details Narrative) - USD ($)	3 Months Ended
	Dec. 31, 2020	Sep. 30, 2020
Debt Disclosure [Abstract]
Loans payable from officers and shareholders		$ 1,165,250
Proceeds from officers and shareholders	$ 295,000
Loans payable to officers and shareholders	1,460,250
Loans payable from officers and shareholders, past due amount	$ 504,250

XML 36 R25.htm IDEA: XBRL DOCUMENT

U.S. Small Business Administration Loan Payable (Details) - USD ($)	3 Months Ended
	Dec. 31, 2020	Sep. 30, 2020
U.s. Small Business Administration Loan Payable
Debt instrument, face amount		$ 37,166
Debt interest rate		1.00%
Debt maturity date	Apr. 23, 2022
Debt maturity description	Beginning in March 2021, PSI is required to make monthly interest payments and all principal and unpaid interest is due in April 2022.
U.S. small business administration loan payable	$ 37,166	$ 37,166

XML 37 R26.htm IDEA: XBRL DOCUMENT

Lease Liabilities (Details Narrative) - USD ($)		1 Months Ended	3 Months Ended
Lease Liabilities (Details Narrative) - USD ($)	Jun. 29, 2020	Feb. 28, 2019	Dec. 31, 2020	Dec. 31, 2019	Sep. 30, 2020
Lease term		24 months
Payment for lease liability		$ 1,850	$ 5,348
Lease expiration date		Jan. 31, 2021
Right of use assets		$ 27,841	1,613		$ 6,961
Lease, discount rate		4.00%
Lease liability			1,613		$ 6,961
Lease rent expense			5,348
Amortization of right of use asset			5,348	$ 5,144
Monthly lease payment			11,000
Lease obligation remaining			$ 631,587
Hanover Hoffman Estates LLC [Member]
Lease rent expense	$ 672,878

XML 38 R27.htm IDEA: XBRL DOCUMENT

Shareholders' Equity (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended
Shareholders' Equity (Details Narrative) - USD ($)	Apr. 30, 2020	Dec. 31, 2020	Sep. 30, 2020	Jan. 02, 2018	Dec. 29, 2017
Common stock, shares authorized		200,000,000	200,000,000
Stock options remaining available shares		12,665,238	14,127,738
Restricted Stock [Member]
Number of vested shares		1,387,500
Stock based compensation		$ 41,625
Unvested compensation		266,625
Stock Option [Member]
Stock based compensation		10,882
Unvested compensation		85,882
Aggregate intrinsic value		$ 126,625
2010 Non-Qualified Stock Option Plan [Member]
Common stock, shares authorized				30,000,000	7,500,000
2010 Non-Qualified Stock Option Plan [Member] \| Stock Option [Member]
Stock options remaining available shares		17,334,762
Vest Monthly from April 2020 Through March 2021 [Member]
Number of vested shares	1,800,000
Vest Monthly from April 2020 Through March 2023 [Member]
Number of vested shares	11,250,000
Vest Over Time [Member]
Number of vested shares	13,050,000
Board of Directors [Member]
Number of restricted shares issued during period, shares	20,170,000
Number of vested shares	7,120,000
Warrant [Member]
Aggregate intrinsic value for warrant

XML 39 R28.htm IDEA: XBRL DOCUMENT

Shareholders' Equity - Summary of Restricted Common Stock (Details)	3 Months Ended
	Dec. 31, 2020 USD ($) $ / shares shares
Equity [Abstract]
Number of Restricted Shares Non-vested, Beginning balance \| shares	10,275,000
Number of Restricted Shares Non-vested, Granted \| shares
Number of Restricted Shares Non-vested, Vested \| shares	(1,387,500)
Number of Restricted Shares Non-vested, Forfeited \| shares
Number of Restricted Shares Non-vested, Ending balance \| shares	8,887,500
Fair Value Non-vested, Beginning balance \| $	$ 308,250
Fair Value Non-vested, Granted \| $
Fair Value Non-vested, Vested \| $	(41,625)
Fair Value Non-vested, Forfeited \| $
Fair Value Non-vested, Ending balance \| $	$ 266,625
Weighted Average Grant Date Fair Value Non-vested, Beginning balance \| $ / shares	$ 0.03
Weighted Average Grant Date Fair Value Non-vested, Granted \| $ / shares
Weighted Average Grant Date Fair Value Non-vested, Vested \| $ / shares	0.03
Weighted Average Grant Date Fair Value Non-vested, Forfeited \| $ / shares
Weighted Average Grant Date Fair Value Non-vested, Ending balance \| $ / shares	$ 0.03

XML 40 R29.htm IDEA: XBRL DOCUMENT

Shareholders' Equity - Schedule of Stock Option Activity (Details)	3 Months Ended
	Dec. 31, 2020 $ / shares shares
Number of Option Shares Outstanding, Number, Beginning balance \| shares	14,127,738
Number of Option Shares Outstanding, Granted \| shares
Number of Option Shares Outstanding, Cancelled \| shares
Number of Option Shares Outstanding, Exercised \| shares
Number of Option Shares Outstanding, Expired \| shares	(1,462,500)
Number of Option Shares Outstanding, Number, Ending balance \| shares	12,665,238
Number of Option Shares Outstanding, Vested and exercisable, Ending balance \| shares	9,702,738
Number of Option Shares Outstanding, Unvested, Ending balance \| shares	2,962,500
Exercise Price Range Per Share, Granted
Exercise Price Range Per Share, Cancelled
Exercise Price Range Per Share, Exercised
Exercise Price Range Per Share, Unvested, Ending balance	0.04
Weighted Average Exercise Price, Number, Beginning balance	0.29
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, Cancelled
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Expired	1.41
Weighted Average Exercise Price, Number, Ending balance	0.10
Weighted Average Exercise Price, Vested and exercisable, Ending balance	0.12
Weighted Average Exercise Price, Unvested, Ending balance	0.04
Minimum [Member]
Exercise Price Range Per Share, Number, Beginning balance	0.03
Exercise Price Range Per Share, Expired	0.14
Exercise Price Range Per Share, Number, Ending balance	0.03
Exercise Price Range Per Share, Vested and exercisable, Ending balance	0.03
Maximum [Member]
Exercise Price Range Per Share, Number, Beginning balance	2.00
Exercise Price Range Per Share, Expired	2.00
Exercise Price Range Per Share, Number, Ending balance	0.40
Exercise Price Range Per Share, Vested and exercisable, Ending balance	$ 0.40

XML 41 R30.htm IDEA: XBRL DOCUMENT

Shareholders' Equity - Schedule of Outstanding and Exercisable Options by Exercise Price Range (Details) - $ / shares	3 Months Ended
	Dec. 31, 2020	Sep. 30, 2020
Range of Exercise Prices, Lower Limit	$ 0.03
Range of Exercise Prices, Upper Limit	$ 0.40
Number of Options, Outstanding, Number	12,665,238	14,127,738
Number of Options, Outstanding, Weighted Average Remaining Contractual Term	6 years 8 months 19 days
Number of Options, Outstanding, Weighted Average Exercise Price	$ 0.10	$ 0.29
Number of Options, Exercisable, Number	9,702,738
Number of Options, Exercisable, Weighted Average Remaining Contractual Term	5 years 9 months 25 days
Number of Options, Exercisable, Weighted Average Exercise Price	$ 0.12
Exercise Price Range One [Member]
Range of Exercise Prices, Lower Limit	0.03
Range of Exercise Prices, Upper Limit	$ 0.39
Number of Options, Outstanding, Number	12,602,738
Number of Options, Outstanding, Weighted Average Remaining Contractual Term	6 years 9 months
Number of Options, Outstanding, Weighted Average Exercise Price	$ 0.09
Number of Options, Exercisable, Number	9,640,238
Number of Options, Exercisable, Weighted Average Remaining Contractual Term	5 years 10 months 6 days
Number of Options, Exercisable, Weighted Average Exercise Price	$ 0.12
Exercise Price Range Two [Member]
Range of Exercise Prices, Upper Limit	$ 0.40
Number of Options, Outstanding, Number	62,500
Number of Options, Outstanding, Weighted Average Remaining Contractual Term	1 year 2 months 30 days
Number of Options, Outstanding, Weighted Average Exercise Price	$ 0.40
Number of Options, Exercisable, Number	62,500
Number of Options, Exercisable, Weighted Average Remaining Contractual Term	1 year 2 months 30 days
Number of Options, Exercisable, Weighted Average Exercise Price	$ 0.40

XML 42 R31.htm IDEA: XBRL DOCUMENT

Shareholders' Equity - Schedule of Warrant Activity (Details) - Warrant [Member]	3 Months Ended
	Dec. 31, 2020 $ / shares shares
Number of Warrant Shares Outstanding, Number, Beginning Balance \| shares	67,634,049
Number of Warrant Shares Outstanding, Granted \| shares
Number of Warrant Shares Outstanding, Cancelled \| shares
Number of Warrant Shares Outstanding, Exercised \| shares
Number of Warrant Shares Outstanding, Expired \| shares
Number of Warrant Shares Outstanding, Number, Ending Balance \| shares	67,634,049
Number of Warrant Shares Outstanding, Vested and exercisable, Ending Balance \| shares	67,634,049
Weighted Average Exercise Price, Number, Beginning Balance	$ 0.16
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, Cancelled
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Expired
Weighted Average Exercise Price, Number, Ending Balance	0.16
Weighted Average Exercise Price, Vested and exercisable, Ending Balance	0.16
Minimum [Member]
Weighted Average Exercise Price, Number, Beginning Balance	0.07
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, Cancelled
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Expired
Weighted Average Exercise Price, Number, Ending Balance	0.07
Weighted Average Exercise Price, Vested and exercisable, Ending Balance	0.07
Maximum [Member]
Weighted Average Exercise Price, Number, Beginning Balance	0.40
Weighted Average Exercise Price, Granted
Weighted Average Exercise Price, Cancelled
Weighted Average Exercise Price, Exercised
Weighted Average Exercise Price, Expired
Weighted Average Exercise Price, Number, Ending Balance	0.40
Weighted Average Exercise Price, Vested and exercisable, Ending Balance	$ 0.40

XML 43 R32.htm IDEA: XBRL DOCUMENT

Shareholders' Equity - Schedule of Outstanding and Exercisable Warrants by Exercise Price Range (Details) - Warrant [Member] - $ / shares	3 Months Ended
	Dec. 31, 2020	Sep. 30, 2020
Range of Exercise Prices, Lower Limit	$ 0.12
Range of Exercise Prices, Upper Limit	$ 0.67
Number of Warrants, Outstanding, Number	67,634,049	67,634,049
Number of Warrants, Outstanding, Weighted Average Remaining Contractual Term	1 year 7 months 13 days
Number of Warrants, Outstanding, Weighted Average Exercise Price	$ 0.16
Number of Warrants, Exercisable, Number	67,634,049
Number of Warrants, Exercisable, Weighted Average Remaining Contractual Term	1 year 7 months 13 days
Number of Warrants, Exercisable, Weighted Average Exercise Price	$ 0.16
Exercise Price Range One [Member]
Range of Exercise Prices, Lower Limit	0.12
Range of Exercise Prices, Upper Limit	$ 0.20
Number of Warrants, Outstanding, Number	60,429,384
Number of Warrants, Outstanding, Weighted Average Remaining Contractual Term	1 year 8 months 26 days
Number of Warrants, Outstanding, Weighted Average Exercise Price	$ 0.15
Number of Warrants, Exercisable, Number	60,429,384
Number of Warrants, Exercisable, Weighted Average Remaining Contractual Term	1 year 8 months 26 days
Number of Warrants, Exercisable, Weighted Average Exercise Price	$ 0.15
Exercise Price Range Two [Member]
Range of Exercise Prices, Lower Limit	0.21
Range of Exercise Prices, Upper Limit	$ 0.40
Number of Warrants, Outstanding, Number	7,204,665
Number of Warrants, Outstanding, Weighted Average Remaining Contractual Term	7 months 21 days
Number of Warrants, Outstanding, Weighted Average Exercise Price		$ 0.26
Number of Warrants, Exercisable, Number	7,204,665
Number of Warrants, Exercisable, Weighted Average Remaining Contractual Term	7 months 21 days
Number of Warrants, Exercisable, Weighted Average Exercise Price	$ 0.26

XML 44 R33.htm IDEA: XBRL DOCUMENT

Segment Reporting - Schedule of Assets of Reportable Segments (Details) - USD ($)	Dec. 31, 2020	Sep. 30, 2020	Feb. 28, 2019
Cash	$ 78,523	$ 51,320
Accounts receivable	23,989
Inventories	134,522	94,560
Prepaid expenses and other current assets	500	500
Total current assets	237,534	146,380
Right-of-use asset	1,613	6,961	$ 27,841
Total other assets	1,613	6,961
TOTAL ASSETS	239,147	$ 153,341
Corporate [Member]
Cash	8,178
Accounts receivable
Inventories
Prepaid expenses and other current assets	500
Total current assets	8,678
Right-of-use asset
Total other assets
TOTAL ASSETS	8,678
Medical Devices [Member]
Cash	67,709
Accounts receivable	23,989
Inventories	134,522
Prepaid expenses and other current assets
Total current assets	226,220
Right-of-use asset	1,613
Total other assets	1,613
TOTAL ASSETS	227,833
Authentication and Encryption [Member]
Cash	2,636
Accounts receivable
Inventories
Prepaid expenses and other current assets
Total current assets	2,636
Right-of-use asset
Total other assets
TOTAL ASSETS	$ 2,636

XML 45 R34.htm IDEA: XBRL DOCUMENT

Segment Reporting - Schedule of Operations of Reportable Segments (Details) - USD ($)	3 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Trade sales	$ 90,499
Cost of goods sold	80,100
Gross profit	10,399
Operating expenses	308,541	337,273
Loss from operations	(298,142)	(337,273)
Corporate [Member]
Trade sales
Cost of goods sold
Gross profit
Operating expenses	49,109	98,462
Loss from operations	(49,109)	(98,462)
Medical Devices [Member]
Trade sales	90,499
Cost of goods sold	80,100
Gross profit	10,399
Operating expenses	256,471	175,286
Loss from operations	(246,072)	(175,286)
Authentication and Encryption [Member]
Trade sales
Cost of goods sold
Gross profit
Operating expenses	2,961	63,525
Loss from operations	$ (2,961)	$ (63,525)

- Definition

Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1,2)
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

+ Details

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

XML 46 R35.htm IDEA: XBRL DOCUMENT

Legal Matters (Details Narrative)	3 Months Ended
Legal Matters (Details Narrative)	Dec. 31, 2020 USD ($)
Interest rate of negotiated settlement	4.00%
Ex- Employee [Member]
Claims amount	$ 21,600
Wages increase rate	2.00%
Former CEO [Member]
Claims amount	$ 179,548
Wages increase rate	2.00%
Claim alleges unpaid wages	$ 158,715
Unpaid vacation amount	$ 20,833

XML 47 R36.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details Narrative) - USD ($)		1 Months Ended	3 Months Ended
Subsequent Events (Details Narrative) - USD ($)	Apr. 01, 2021	Apr. 30, 2020	Dec. 31, 2020	Apr. 07, 2021
Loans payable to related parties			$ 1,460,250
Number of stock options granted to purchase
Number of stock options cancelled
Board of Directors [Member]
Number of restricted shares issued during period, shares		20,170,000
Number of vested shares		7,120,000
Subsequent Event [Member]
Loans payable to related parties				$ 355,000
Subsequent Event [Member] \| Board of Directors [Member] \| April 2023 Through March 2024 [Member]
Number of restricted shares issued during period, shares	3,750,000
Fair value of options granted	$ 187,500
Subsequent Event [Member] \| Officers and Directors [Member]
Number of restricted shares issued during period, shares	10,085,714
Fair value of options granted	$ 504,286
Number of vested shares	7,060,000
Subsequent Event [Member] \| Officers and Directors [Member] \| April 2025 [Member]
Number of vested shares	3,025,714
Subsequent Event [Member] \| CEO [Member]
Fair value of options granted	$ 670,000
Number of vested shares	9,052,500
Number of stock options granted to purchase	13,449,429
Share exercise price	$ 0.05
Subsequent Event [Member] \| CEO [Member] \| April 2023 Through March 2024 [Member]
Fair value of options granted	$ 65,000
Number of stock options granted to purchase	1,300,000
Share exercise price	$ 0.05
Subsequent Event [Member] \| CEO [Member] \| April 2025 [Member]
Number of vested shares	4,396,929
Subsequent Event [Member] \| CEO [Member] \| September 2021 through December 2021 [Member]
Number of stock options cancelled	5,277,778

EXCEL 48 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 50 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 51 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 125 291 1 true 43 0 false 4 false false R1.htm 00000001 - Document - Document and Entity Information Sheet http://wellnesscenterusa.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://wellnesscenterusa.com/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://wellnesscenterusa.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://wellnesscenterusa.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Shareholders' Deficit (Unaudited) Sheet http://wellnesscenterusa.com/role/StatementsOfShareholdersDeficit Condensed Consolidated Statements of Shareholders' Deficit (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://wellnesscenterusa.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - Basis of Presentation Sheet http://wellnesscenterusa.com/role/BasisOfPresentation Basis of Presentation Notes 7 false false R8.htm 00000008 - Disclosure - Summary of Significant Accounting Policies Sheet http://wellnesscenterusa.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 00000009 - Disclosure - Loans Payable from Officers and Shareholders Sheet http://wellnesscenterusa.com/role/LoansPayableFromOfficersAndShareholders Loans Payable from Officers and Shareholders Notes 9 false false R10.htm 00000010 - Disclosure - U.S. Small Business Administration Loan Payable Sheet http://wellnesscenterusa.com/role/U.s.SmallBusinessAdministrationLoanPayable U.S. Small Business Administration Loan Payable Notes 10 false false R11.htm 00000011 - Disclosure - Lease Liabilities Sheet http://wellnesscenterusa.com/role/LeaseLiabilities Lease Liabilities Notes 11 false false R12.htm 00000012 - Disclosure - Shareholders' Equity Sheet http://wellnesscenterusa.com/role/ShareholdersEquity Shareholders' Equity Notes 12 false false R13.htm 00000013 - Disclosure - Segment Reporting Sheet http://wellnesscenterusa.com/role/SegmentReporting Segment Reporting Notes 13 false false R14.htm 00000014 - Disclosure - Legal Matters Sheet http://wellnesscenterusa.com/role/LegalMatters Legal Matters Notes 14 false false R15.htm 00000015 - Disclosure - Subsequent Events Sheet http://wellnesscenterusa.com/role/SubsequentEvents Subsequent Events Notes 15 false false R16.htm 00000016 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://wellnesscenterusa.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://wellnesscenterusa.com/role/SummaryOfSignificantAccountingPolicies 16 false false R17.htm 00000017 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://wellnesscenterusa.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://wellnesscenterusa.com/role/SummaryOfSignificantAccountingPolicies 17 false false R18.htm 00000018 - Disclosure - Shareholders' Equity (Tables) Sheet http://wellnesscenterusa.com/role/ShareholdersEquityTables Shareholders' Equity (Tables) Tables http://wellnesscenterusa.com/role/ShareholdersEquity 18 false false R19.htm 00000019 - Disclosure - Segment Reporting (Tables) Sheet http://wellnesscenterusa.com/role/SegmentReportingTables Segment Reporting (Tables) Tables http://wellnesscenterusa.com/role/SegmentReporting 19 false false R20.htm 00000020 - Disclosure - Basis of Presentation (Details Narrative) Sheet http://wellnesscenterusa.com/role/BasisOfPresentationDetailsNarrative Basis of Presentation (Details Narrative) Details http://wellnesscenterusa.com/role/BasisOfPresentation 20 false false R21.htm 00000021 - Disclosure - Summary of Significant Accounting Policies (Details Narrative) Sheet http://wellnesscenterusa.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative Summary of Significant Accounting Policies (Details Narrative) Details http://wellnesscenterusa.com/role/SummaryOfSignificantAccountingPoliciesTables 21 false false R22.htm 00000022 - Disclosure - Summary of Significant Accounting Policies - Schedule of Company's Consolidated Subsidiaries (Details) Sheet http://wellnesscenterusa.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfCompanysConsolidatedSubsidiariesDetails Summary of Significant Accounting Policies - Schedule of Company's Consolidated Subsidiaries (Details) Details 22 false false R23.htm 00000023 - Disclosure - Summary of Significant Accounting Policies - Schedule of Company's Consolidated Subsidiaries (Details) (Parenthetical) Sheet http://wellnesscenterusa.com/role/SummaryOfSignificantAccountingPolicies-ScheduleOfCompanysConsolidatedSubsidiariesDetailsParenthetical Summary of Significant Accounting Policies - Schedule of Company's Consolidated Subsidiaries (Details) (Parenthetical) Details 23 false false R24.htm 00000024 - Disclosure - Loans Payable from Officers and Shareholders (Details Narrative) Sheet http://wellnesscenterusa.com/role/LoansPayableFromOfficersAndShareholdersDetailsNarrative Loans Payable from Officers and Shareholders (Details Narrative) Details http://wellnesscenterusa.com/role/LoansPayableFromOfficersAndShareholders 24 false false R25.htm 00000025 - Disclosure - U.S. Small Business Administration Loan Payable (Details) Sheet http://wellnesscenterusa.com/role/U.s.SmallBusinessAdministrationLoanPayableDetails U.S. Small Business Administration Loan Payable (Details) Details http://wellnesscenterusa.com/role/U.s.SmallBusinessAdministrationLoanPayable 25 false false R26.htm 00000026 - Disclosure - Lease Liabilities (Details Narrative) Sheet http://wellnesscenterusa.com/role/LeaseLiabilitiesDetailsNarrative Lease Liabilities (Details Narrative) Details http://wellnesscenterusa.com/role/LeaseLiabilities 26 false false R27.htm 00000027 - Disclosure - Shareholders' Equity (Details Narrative) Sheet http://wellnesscenterusa.com/role/ShareholdersEquityDetailsNarrative Shareholders' Equity (Details Narrative) Details http://wellnesscenterusa.com/role/ShareholdersEquityTables 27 false false R28.htm 00000028 - Disclosure - Shareholders' Equity - Summary of Restricted Common Stock (Details) Sheet http://wellnesscenterusa.com/role/ShareholdersEquity-SummaryOfRestrictedCommonStockDetails Shareholders' Equity - Summary of Restricted Common Stock (Details) Details 28 false false R29.htm 00000029 - Disclosure - Shareholders' Equity - Schedule of Stock Option Activity (Details) Sheet http://wellnesscenterusa.com/role/ShareholdersEquity-ScheduleOfStockOptionActivityDetails Shareholders' Equity - Schedule of Stock Option Activity (Details) Details 29 false false R30.htm 00000030 - Disclosure - Shareholders' Equity - Schedule of Outstanding and Exercisable Options by Exercise Price Range (Details) Sheet http://wellnesscenterusa.com/role/ShareholdersEquity-ScheduleOfOutstandingAndExercisableOptionsByExercisePriceRangeDetails Shareholders' Equity - Schedule of Outstanding and Exercisable Options by Exercise Price Range (Details) Details 30 false false R31.htm 00000031 - Disclosure - Shareholders' Equity - Schedule of Warrant Activity (Details) Sheet http://wellnesscenterusa.com/role/ShareholdersEquity-ScheduleOfWarrantActivityDetails Shareholders' Equity - Schedule of Warrant Activity (Details) Details 31 false false R32.htm 00000032 - Disclosure - Shareholders' Equity - Schedule of Outstanding and Exercisable Warrants by Exercise Price Range (Details) Sheet http://wellnesscenterusa.com/role/ShareholdersEquity-ScheduleOfOutstandingAndExercisableWarrantsByExercisePriceRangeDetails Shareholders' Equity - Schedule of Outstanding and Exercisable Warrants by Exercise Price Range (Details) Details 32 false false R33.htm 00000033 - Disclosure - Segment Reporting - Schedule of Assets of Reportable Segments (Details) Sheet http://wellnesscenterusa.com/role/SegmentReporting-ScheduleOfAssetsOfReportableSegmentsDetails Segment Reporting - Schedule of Assets of Reportable Segments (Details) Details 33 false false R34.htm 00000034 - Disclosure - Segment Reporting - Schedule of Operations of Reportable Segments (Details) Sheet http://wellnesscenterusa.com/role/SegmentReporting-ScheduleOfOperationsOfReportableSegmentsDetails Segment Reporting - Schedule of Operations of Reportable Segments (Details) Details 34 false false R35.htm 00000035 - Disclosure - Legal Matters (Details Narrative) Sheet http://wellnesscenterusa.com/role/LegalMattersDetailsNarrative Legal Matters (Details Narrative) Details http://wellnesscenterusa.com/role/LegalMatters 35 false false R36.htm 00000036 - Disclosure - Subsequent Events (Details Narrative) Sheet http://wellnesscenterusa.com/role/SubsequentEventsDetailsNarrative Subsequent Events (Details Narrative) Details http://wellnesscenterusa.com/role/SubsequentEvents 36 false false All Reports Book All Reports wcui-20201231.xml wcui-20201231.xsd wcui-20201231_cal.xml wcui-20201231_def.xml wcui-20201231_lab.xml wcui-20201231_pre.xml http://xbrl.sec.gov/dei/2020-01-31 http://fasb.org/srt/2020-01-31 http://fasb.org/us-gaap/2020-01-31 true true ZIP 53 0001493152-21-008229-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-21-008229-xbrl.zip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

Shareholders' Equity - Summary of Restricted Common Stock (Details)	3 Months Ended
	Dec. 31, 2020 USD ($) $ / shares shares
Equity [Abstract]
Number of Restricted Shares Non-vested, Beginning balance \| shares	10,275,000
Number of Restricted Shares Non-vested, Granted \| shares
Number of Restricted Shares Non-vested, Vested \| shares	(1,387,500)
Number of Restricted Shares Non-vested, Forfeited \| shares
Number of Restricted Shares Non-vested, Ending balance \| shares	8,887,500
Fair Value Non-vested, Beginning balance \| $	$ 308,250
Fair Value Non-vested, Granted \| $
Fair Value Non-vested, Vested \| $	(41,625)
Fair Value Non-vested, Forfeited \| $
Fair Value Non-vested, Ending balance \| $	$ 266,625
Weighted Average Grant Date Fair Value Non-vested, Beginning balance \| $ / shares	$ 0.03
Weighted Average Grant Date Fair Value Non-vested, Granted \| $ / shares
Weighted Average Grant Date Fair Value Non-vested, Vested \| $ / shares	0.03
Weighted Average Grant Date Fair Value Non-vested, Forfeited \| $ / shares
Weighted Average Grant Date Fair Value Non-vested, Ending balance \| $ / shares	$ 0.03